Volcano (VOLC) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Volcano Corp	'
Entity Central Index Key	'0001354217	'
Trading Symbol	'volc	'
Entity Filer Category	'Large Accelerated Filer	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	51,603,468

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$31,959	$107,159
Short-term available-for-sale investments	140,894	230,775
Accounts receivable, net	78,755	81,962
Inventories	76,342	60,970
Prepaid expenses and other current assets	34,485	28,525
Total current assets	362,435	509,391
Long-term available-for-sale investments	44,244	34,750
Property and equipment, net	122,077	118,094
Intangible assets, net	124,807	58,108
Goodwill	150,882	55,087
Other non-current assets	60,611	56,489
Total assets	865,056	831,919
Current liabilities:	'	'
Accounts payable	11,152	19,137
Accrued compensation	28,168	26,918
Accrued expenses and other current liabilities	27,060	28,453
Deferred revenues	11,203	10,652
Current maturities of convertible senior notes	23,882	0
Contingent consideration	365	3,750
Total current liabilities	101,830	88,910
Convertible senior notes	392,045	401,012
Deferred revenues	4,797	5,079
Contingent consideration, non-current portion	53,379	29,888
Other non-current liabilities	7,727	7,228
Total liabilities	559,778	532,117
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, par value of $0.001; 10,000 shares authorized; no shares issued and outstanding at September 30, 2014 and December 31, 2013	0	0
Common stock, par value of $0.001; 250,000 shares authorized at September 30, 2014 and December 31, 2013; 51,603 and 51,530 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	52	52
Additional paid-in capital	443,329	420,234
Accumulated other comprehensive loss	-3,085	-4,088
Accumulated deficit	-135,018	-116,396
Total stockholders’ equity	305,278	299,802
Total liabilities and stockholders’ equity	$865,056	$831,919

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	51,603,000	51,530,000
Common stock, shares outstanding	51,603,000	51,530,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenues	$97,457	$95,809	$294,590	$290,384
Cost of revenues, excluding amortization of intangibles	37,292	33,458	110,086	102,624
Gross profit	60,165	62,351	184,504	187,760
Operating expenses:	'	'	'	'
Selling, general and administrative	47,400	45,479	147,064	134,784
Research and development	13,508	16,609	41,165	50,214
Amortization of intangibles	2,804	834	6,405	2,488
Acquisition-related items	1,596	1,253	-3,809	3,742
Restructuring (benefits) charges	-229	4,616	-197	4,874
Total operating expenses	65,079	68,791	190,628	196,102
Operating loss	-4,914	-6,440	-6,124	-8,342
Interest income	237	327	833	970
Interest expense	-7,370	-6,756	-21,868	-19,908
Exchange rate gain (loss)	20	54	91	-1,025
Other, net	56	-33	180	4,144
Loss before income tax	-11,971	-12,848	-26,888	-24,161
Income tax benefit	-3,971	-4,392	-8,266	-10,156
Net loss	($8,000)	($8,456)	($18,622)	($14,005)
Net loss per share:	'	'	'	'
Basic (in dollars per share)	($0.16)	($0.15)	($0.36)	($0.26)
Diluted (in dollars per share)	($0.16)	($0.15)	($0.36)	($0.26)
Shares used in calculating net loss per share:	'	'	'	'
Basic (in shares)	51,529	54,652	51,596	54,466
Diluted (in shares)	51,529	54,652	51,596	54,466

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Loss (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($8,000)	($8,456)	($18,622)	($14,005)
Other comprehensive (loss) income	'	'	'	'
Foreign currency translation adjustments	-2,797	1,522	-1,044	1,527
Changes in unrealized (loss) gain on available-for-sale investments, net of tax	'	'	'	'
Changes in unrealized (loss) gain on available-for-sale investments, net of tax	-92	190	-132	-4
Changes in unrealized gain (loss) on foreign currency forward exchange contracts, net of tax	'	'	'	'
Changes in unrealized gain (loss) on foreign currency forward exchange contracts, net of tax	2,799	-422	2,179	-414
Other comprehensive (loss) income	-90	1,290	1,003	1,109
Comprehensive loss	($8,090)	($7,166)	($17,619)	($12,896)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Stockholders' Equity (unaudited) (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
Beginning Balance at Dec. 31, 2013	$299,802	$52	$420,234	($4,088)	($116,396)
Beginning Balance (shares) at Dec. 31, 2013	'	51,530,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Issuance of common stock under equity compensation plans	12,663	1	12,662	'	'
Issuance of common stock under equity compensation plans, shares	'	1,222,000	'	'	'
Employee stock-based compensation cost	10,726	'	10,726	'	'
Common stock repurchase/retirement	1	-1	2	'	'
Common stock repurchase/retirement, shares	'	-1,149,000	'	'	'
Tax expense related to stock-based compensation	-295	'	-295	'	'
Net loss	-18,622	'	'	'	-18,622
Other comprehensive income	1,003	'	'	1,003	'
Ending Balance at Sep. 30, 2014	$305,278	$52	$443,329	($3,085)	($135,018)
Ending Balance (shares) at Sep. 30, 2014	'	51,603,000	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements Of Cash Flows (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($18,622)	($14,005)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization	24,022	18,677
Amortization (accretion) of investment premium (discount), net	2,567	2,305
Accretion of debt discount on convertible senior notes and other liabilities	15,048	14,148
Change in contingent consideration	-4,841	2,537
Non-cash stock compensation expense	10,721	12,098
Asset impairment related to restructuring	818	4,616
Gain on sale of other long-term investment	-365	-4,153
Effect of exchange rate changes and others	682	10,797
Deferred income taxes	2,211	0
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	665	-3,249
Inventories	-14,699	-15,195
Prepaid expenses and other assets	-16,330	-16,834
Accounts payable	-9,669	-2,599
Accrued compensation	1,671	-535
Accrued expenses and other liabilities	25	983
Deferred revenues	486	-550
Net cash (used in) provided by operating activities	-5,610	9,041
Investing activities	'	'
Purchase of short-term and long-term available-for-sale securities	-161,882	-342,715
Sale or maturity of short-term and long-term available-for-sale securities	239,499	247,790
Cash paid related to acquisitions, net of cash acquired	-114,791	-15,000
Capital expenditures	-22,854	-26,533
Cash paid for intangible assets and other investments	-4,987	-2,377
Proceeds from sale of other long-term investments	665	5,654
Net cash used in investing activities	-64,350	-133,181
Financing activities	'	'
Repayment of capital lease and other liabilities	-179	-22
Cash paid for contingent liability related to acquisitions	-16,900	0
Proceeds from sale of common stock under employee stock purchase plan	3,140	3,576
Proceeds from exercise of common stock options	9,523	2,203
Net cash (used in) provided by financing activities	-4,416	5,757
Effect of exchange rate changes on cash and cash equivalents	-824	-846
Net decrease in cash and cash equivalents	-75,200	-119,229
Cash and cash equivalents, beginning of period	107,159	330,635
Cash and cash equivalents, end of period	31,959	211,406
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	4,745	4,542
Cash paid for income taxes	$2,185	$3,103

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation and Nature of Operations
	The unaudited condensed consolidated financial statements of Volcano Corporation (“we,” “us,” “our,” “Volcano” or the “Company”) contained in this quarterly report on Form 10-Q include our financial statements and the financial statements of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the U.S., or GAAP. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2013.
	The results of operations for the nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
	Reclassification
	Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current year presentation.
	Net Loss Per Share
	Basic net loss per share is computed by dividing consolidated net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing consolidated net loss by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period. Our potentially dilutive shares include outstanding common stock options, unvested restricted stock units, including those with performance or market conditions, and incremental shares issuable upon the conversion of the Convertible Senior Notes or upon exercise of the warrants relating to the Convertible Senior Notes. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income per share as discussed in the following paragraph. For the three months ended September 30, 2014 and 2013, 176,000 and 730,000 in the money option and award shares were dilutive for the period and potentially dilutive shares totaling 49.0 million and 21.5 million have not been included in the computation of diluted net income per share, as the result would be anti-dilutive. For the nine months ended September 30, 2014 and 2013, 571,000 and 872,000 in the money option and award shares were dilutive for the period and potentially dilutive shares totaling 31.7 million and 20.8 million have not been included in the computation of diluted net loss per share, as the result would be anti-dilutive.
	Diluted net loss per common share does not include any incremental shares related to the Convertible Senior Notes for the three and nine months ended September 30, 2014 and 2013. Because the principal amount of the Convertible Senior Notes will be settled in cash upon conversion, only the conversion spread relating to the Convertible Senior Notes may be included in our calculation of diluted net loss per common share. As such, the Convertible Senior Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2.875% Convertible Senior Notes due 2015, or the 2015 Notes, and $32.83 for the 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, subject to adjustments) of the Notes. In addition, the diluted net loss per common share does not include any incremental shares related to the exercise of the warrants related to the Notes for the three and nine months ended September 30, 2014 and 2013. The warrants will not have an impact on diluted net income (loss) per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the warrants issued in connection with the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
	The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes, are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
	On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received a total of 4,705,683 shares of our common stock (see Note 5 "Stockholders' Equity"), of which 3,557,137 shares of our common stock were delivered in December 2013 and 1,148,546 shares of our common stock were delivered in March 2014. The weighted average number of the shares received was removed from the denominator of the basic and diluted net loss per share calculation at the share delivery date.
	The basic and diluted net loss per common share calculations for the three and nine months ended September 30, 2014 and 2013 are as follows (in thousands, except per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss	$	(8,000	)	$	(8,456	)	$	(18,622	)	$	(14,005	)
	Weighted average common shares outstanding for basic	51,529			54,652			51,596			54,466
	Weighted average common shares outstanding for diluted	51,529			54,652			51,596			54,466
	Net loss per share:
	Basic	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)
	Diluted	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)
	Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update, or ASU, 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. The updated guidance is effective for us beginning in fiscal year 2015. The Company is currently evaluating the new standard to determine the effect, if any, on our consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a single comprehensive model for accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for us beginning in fiscal year 2017 and early application is not permitted. The Company is currently evaluating the new standard to determine the effect, if any, on our consolidated financial statements.

Acquisitions_and_AcquisitionRe

Acquisitions and Acquisition-Related Items	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions and Acquisition-Related Items	'
	Acquisitions and Acquisition-Related Items
	AtheroMed Acquisition
	On June 17, 2014, we completed the acquisition of all outstanding equity interests in AtheroMed, Inc., or AtheroMed, a privately-held company engaged in the development of atherectomy technology used in the treatment of peripheral artery disease, or PAD. AtheroMed’s Phoenix® Atherectomy System, or Phoenix, received 510(k) clearance in January 2014, has a CE Mark, and has reimbursement in the U.S. and select countries in Europe. The primary reasons for the acquisition were to diversify our product offerings and to allow us the opportunity to better position ourselves in the peripheral vascular market. The transaction was accounted for as a business combination. The operating results of AtheroMed from the date of acquisition are included in our unaudited condensed consolidated financial statements.
	We paid approximately $116.5 million in cash at closing, which amount was partially offset by our acquisition at closing of approximately $1.7 million in cash. In addition, we agreed to pay a cash milestone of $15.0 million if FDA clearance of a premarket 510(k) notification is received on or before November 15, 2014 for AtheroMed's second generation Phoenix Atherectomy System. The fair market value of this contingent consideration was estimated to be $14.0 million at acquisition. The 510(k) notification was submitted and approved by the FDA during the third quarter of 2014, and the $15.0 million cash milestone was paid during the third quarter of 2014.
	Furthermore, we may be required to make payments upon reaching certain sales milestones. We estimate the contingent sales milestone payments to be approximately $39.4 million and the fair value of this contingent consideration was preliminarily estimated to be $29.0 million at acquisition. We determined the fair value of the contingent consideration relative to the milestone payments based on commercial sales of AtheroMed products using various estimates, including revenue projections, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At September 30, 2014, for the fair value relative to the milestone payments based on the commercial sales of AtheroMed products, the key assumptions in applying the income approach include an 11% discount rate and probability-weighted expected milestone payment ranges from $32.8 million to $49.2 million based on estimated commercial sales of AtheroMed products ranging from $59.9 million to $89.9 million from 2015 to 2017. Using different valuation assumptions could result in significant differences in the fair value of the contingent consideration and accretion expense in the current or future periods.
	The assets acquired, consisting primarily of developed technology valued at $61.9 million and IPR&D valued at $9.0 million, were recorded at their estimated fair values as of the acquisition date. The estimated fair value of the IPR&D was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after tax cash flows attributable to that intangible asset. The fair value using the multi-period excess earnings method was dependent on an estimated weighted average cost of capital for AtheroMed of 11%, which represents a rate of return that a market participant would expect for these assets.
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		30-Sep-14
		Three months ended			Nine months ended
	Fair value measurement at beginning of period / acquisition	$	43,145		$	43,000
	Change in fair value measurement included in operating expenses	1,783			1,928
	Contingent consideration settled	(15,053		)	(15,053		)
	Fair value measurement at end of period	29,875			29,875
	The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed is $95.8 million, which represents the goodwill amount resulting from the acquisition, was allocated to our medical segment and is not deductible for income tax purposes. We expect to benefit from the acquisition by expanding our product offerings to physicians thereby contributing to an expanded revenue base. Further, we expect to realize synergies by offering the products developed from the acquisition utilizing our existing sales force.
	As of the date of this Quarterly Report on Form 10-Q, the Company is still finalizing the allocation of the purchase price and the valuation of its contingent consideration. Changes to the current allocation and contingent consideration may occur as additional information becomes available including, but not limited to, the valuation of inventory, fixed assets, intangible assets and deferred taxes, with such changes recorded as an adjustment to goodwill.
	The acquisition was not individually or collectively considered material to the overall unaudited condensed consolidated financial statements and results of operations of the Company.
	Pioneer Acquisition
	On August 30, 2013, we completed the acquisition of the Pioneer Plus re-entry catheter product line, or Pioneer, from Medtronic, Inc. or Medtronic. The product line is an interventional medical device designed to enable the crossing of sub-total, total and chronic total occlusions within the peripheral vasculature, potentially eliminating the need for surgery. The primary reason for the acquisition was to increase our penetration of the peripheral vascular market with a therapeutic product offering and continue to diversify our product offerings beyond coronary applications. The transaction was accounted for as a business combination. The operating results of Pioneer from the date of acquisition were included in our unaudited condensed consolidated financial statements.
	The aggregate purchase price was $15.0 million. The assets acquired, primarily $12.7 million of intangible assets, were recorded at their estimated fair values as of the acquisition date. The excess of purchase price over the fair value of the assets acquired and liabilities assumed was $1.5 million, which represented the goodwill amount resulting from the acquisition and was allocated to our medical segment and is not deductible for income tax purposes.
	The acquisition was not individually or collectively considered material to the overall unaudited condensed consolidated financial statements and the results of the Company’s operations.
	Crux Acquisition
	On December 12, 2012 we completed the acquisition of all outstanding equity interests in Crux Biomedical, Inc., or Crux, a privately-held company engaged in the development of filter technology for the vascular, cardiovascular and interventional radiology markets. The primary reason for the acquisition was to diversify our product offerings, allow us the opportunity to better position ourselves in the peripheral vascular market and to increase our IVUS product sales. The transaction was accounted for as a business combination. The operating results of Crux from the date of acquisition were included in our unaudited condensed consolidated financial statements.
	Under the merger agreement and the amendment to the merger agreement, we agreed to pay a cash milestone payment of $3.0 million following the achievement of written clearance by the U.S. Food and Drug Administration, or FDA, of a 510(k) notification for the commercial sale in the United States of an inferior vena cava filter retrieval device developed by Crux, provided such 510(k) notification was submitted on or before November 30, 2013. The 510(k) notification was submitted on November 30, 2013 and was approved by FDA during the first quarter of 2014. The $3.0 million cash milestone was paid during the first quarter of 2014.
	In addition, subject to the terms of the merger agreement, we may be required to make payments upon reaching various sales milestones. We determined the fair value of the contingent consideration relative to the milestone payments based on commercial sales of Crux products using various estimates, including revenue projections, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At September 30, 2014, for the fair value relative to the milestone payments based on the commercial sales of Crux products, the key assumptions in applying the income approach include a 10% discount rate and probability-weighted expected milestone payment ranges from $23.4 million to $64.3 million based on estimated commercial sales of Crux products ranging from $94.4 million to $204.9 million from 2014 to 2019. During the second quarter of 2014, we reduced the future revenue estimates based on our initial commercial experience. Offsetting the reduction in the liability related to the change in future revenue estimates was a reduction in the discount rate from 14% to 10% to reflect a reduction in the risk premium associated with commercialization now that the product is in full market release. Using different valuation assumptions could result in significant differences in the fair value of the contingent consideration and accretion expense in the current or future periods.
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net of working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Fair value measurement at beginning of period	$	24,290		$	31,687		$	33,638		$	30,231
	Change in fair value measurement included in operating expenses	(421		)	881			(6,769		)	2,337
	Contingent consideration settled	—			—			(3,000		)	—
	Fair value measurement at end of period	23,869			32,568			23,869			32,568
	Sync-Rx Acquisition
	On November 26, 2012, we acquired all of the outstanding equity interests in Sync-Rx Ltd., or Sync-Rx, a privately-held company, which is engaged in the development of advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. The Sync-Rx technology will provide us with a platform on which to build a range of advanced software features that will aid clinical decision-making by providing angiography and intra-body image enhancement, measurement and non-invasive imaging and intravascular co-registration capabilities, and future opportunities in physiology and peripheral and minimally invasive structural heart therapy guidance. The transaction was accounted for as a business combination. The operating results of Sync-Rx from the date of acquisition were included in our unaudited condensed consolidated financial statements.
	In connection with the acquisition, we recorded a contingent liability of $1.1 million related to a government grant received to develop underlying technologies. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technologies for which grant proceeds were received. We expect to generate revenues sufficient to repay the liability in its entirety. The grant was recorded as other liabilities at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At acquisition, for the fair value relative to this liability, the key assumptions in applying the income approach included an 8% discount rate and estimated commercial sales derived from the underlying technology ranging from $256.1 million to $298.3 million over the expected period of re-payment of 10 to 16 years. The long-term liability will be accreted to the re-payment amount of $1.9 million plus interest, with such accretion recorded as interest expense over the expected period of re-payment. As of September 30, 2014, there were no significant changes in the range of outcomes for the contingent liability recognized as a result of the acquisition.
	Acquisition-Related Items
	During the three months ended September 30, 2014, we recorded expense of $1.6 million from acquisition-related items, including $244,000 of transaction costs primarily associated with the AtheroMed and Sync-Rx acquisitions; and expense of $1.4 million, related to the change in fair value of the contingent consideration associated with the Crux and AtheroMed acquisitions, primarily due to passage of time.
	During the nine months ended September 30, 2014, we recorded income of $3.8 million from acquisition-related items, including $1.0 million of transaction costs primarily associated with the AtheroMed and Sync-Rx acquisitions; and income of $4.8 million related to the change in fair value of the contingent consideration associated with the Crux and AtheroMed acquisitions, primarily due to the revised revenue forecasts for Crux, partially offset by a change in the discount factor for Crux and the passage of time for both acquisitions.
	During the three and nine months ended September 30, 2013, we recorded charges of $1.3 million and $3.7 million, respectively, in acquisition-related items, including charges of $881,000 and $2.5 million, respectively, related to the change in fair value of the contingent consideration associated with the Crux acquisition, which is primarily due to the passage of time, and $358,000 and $810,000, respectively, in transaction costs primarily associated with the Crux and Pioneer acquisitions.

Financial_Statement_Details

Financial Statement Details	9 Months Ended
	Sep. 30, 2014
Financial Statement Details [Abstract]	'
Financial Statement Details	'
	Financial Statement Details
	Cash and Cash Equivalents and Available-for-Sale Investments
	We invest our excess funds in U.S. government securities, corporate fixed income securities, commercial paper, certificates of deposit and money market funds. As of September 30, 2014, all of these investments were classified as available-for-sale and mature within 22 months. These investments are recorded at their estimated fair value, with unrealized gains or losses reported as a separate component of accumulated other comprehensive income or loss.
	At September 30, 2014 and December 31, 2013, available-for-sale investments are detailed as follows (in thousands):
	At September 30, 2014
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	140,927			$	29			$	62			$	140,894
	Short-term available-for-sale investments		$	140,927			$	29			$	62			$	140,894
	Long-term:
	Corporate debt securities		$	44,317			$	—			$	73			$	44,244
	Long-term available for sale investments		$	44,317			$	—			$	73			$	44,244
	At December 31, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	164,570			$	72			$	4			$	164,638
	U.S. Treasury and agency debt securities		66,153				2				18				66,137
	Short-term available-for-sale investments		$	230,723			$	74			$	22			$	230,775
	Long-term:
	Corporate debt securities		$	11,697			$	30			$	—			$	11,727
	U.S. Treasury and agency debt securities		23,008				15				—				23,023
	Long-term available for sale investments		$	34,705			$	45			$	—			$	34,750
	Available-for-sale investments that are in an unrealized loss position at September 30, 2014 and December 31, 2013 are detailed as follows (in thousands):
			At September 30, 2014
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	106,244			$	135
			At December 31, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	21,226			$	4
	U.S. Treasury and agency debt securities		40,982				18
			$	62,208			$	22
	Derivative Financial Instruments
	Foreign Currency Forward Contracts
	We are exposed to foreign currency risks through our global operations, primarily in Japan and Europe, and when we enter into transactions in non-functional currencies. Exchange rate fluctuations between the U.S. dollar and foreign currencies, primarily the Japanese yen, or yen, and the euro, could adversely affect our financial results. We use derivative financial instruments to mitigate our foreign currency exposures. We do not enter into derivative instruments for speculative purposes.
	We enter into derivative financial instruments, principally forward contracts, to manage a portion of the foreign currency risk related to transactions in non-functional currencies. We record derivative financial instruments as either assets or liabilities in our unaudited condensed consolidated balance sheets and measure them at fair value. Certain of the derivative instruments we use to mitigate this exposure are not designated for hedge accounting treatment, and as a result, changes in their fair values are recorded in exchange rate gain (loss) in the unaudited condensed consolidated statement of operations.
	We hedge forecasted intercompany inventory transactions that are denominated in yen and euro. Forward contracts are used to hedge forecasted intercompany inventory transactions over specific time periods. These forward contracts are designated as cash flow hedges and have maturity dates of up to 22 months. Changes in the fair value of cash flow hedges, excluding time value of the hedges which is recorded as interest expense, are reported as a component of accumulated other comprehensive income (loss), or AOCI, within stockholders' equity. Once the underlying hedged transaction occurs, we de-designate the derivative, cease to apply hedge accounting treatment to the transaction, reclassify the gain or loss recorded to date from AOCI into cost of sales, and record any further gains or losses to exchange rate gain (loss). We evaluate hedge effectiveness at the inception of the hedge and on an ongoing basis. To the extent we experience ineffectiveness in our hedges, the gains or losses accumulated in other comprehensive income associated with the ineffective portion of the hedge are reclassified immediately into exchange rate gain (loss). We adjust the level and use of derivatives as soon as practicable after learning that an exposure has changed. We review all exposures on derivative positions on a regular basis.
	At September 30, 2014 and December 31, 2013, the notional amount of our outstanding forward contracts was $120.4 million and $97.3 million, respectively, of which $56.4 million and $40.3 million, respectively, were designated as cash flow hedges. At September 30, 2014, our outstanding forward contracts mature through November 2015.
	As of September 30, 2014, the deferred gain, net of tax, for those derivative contracts that qualified for hedge accounting treatment was $2.6 million, all of which will be reclassified from accumulated other comprehensive income (loss) into cost of sales at the then-current values over the next twelve months as the underlying hedged transactions are recognized.
	The following tables summarize the location and fair values of derivative instruments on our unaudited condensed consolidated balance sheets (in thousands) at September 30, 2014 and December 31, 2013. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		At September 30, 2014
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	3,685			Other current liabilities		$	1
	Foreign exchange forward contracts	Other long-term assets		140				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			3,825						1
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		4,033				Other current liabilities		26
	Total Derivatives Not Designated as Hedging Instruments			4,033						26
	Total Derivatives			$	7,858					$	27
		As of December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	954			Other current liabilities		$	251
	Foreign exchange forward contracts	Other long-term assets		81				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			1,035						251
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		1,953				Other current liabilities		1,164
Total Derivatives Not Designated as Hedging Instruments			1,953						1,164
Total Derivatives			$	2,988					$	1,415
The Company has elected to present the fair value of derivative assets and liabilities within the unaudited condensed consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information (in thousands) as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.
	As of September 30, 2014
					Gross Amount Not Offset on the Balance Sheet
	Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
Derivative Assets
Foreign exchange forward contracts	$	7,858			$	(27	)		—			$	7,831
Derivative Liabilities
Foreign exchange forward contracts	(27		)		27				—			—
Total	$	7,831			—				—			7,831
	As of December 31, 2013
					Gross Amount Not Offset on the Balance Sheet
	Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
Derivative Assets
Foreign exchange forward contracts	$	2,988			$	(1,415	)		—			$	1,573
Derivative Liabilities
Foreign exchange forward contracts	(1,415		)		1,415				—			—
Total	$	1,573			—				—			1,573
The following table summarizes the effect of our foreign exchange forward contracts on our unaudited Condensed Consolidated Statements of Operations (in thousands).
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
Derivatives Designated as Hedging Instruments
Gain (loss) recognized in other comprehensive income on foreign currency		$	4,243			$	(727	)		$	3,585			$	(719	)
forward contracts (effective portion)
Gain (loss) reclassified from accumulated other comprehensive income		16				(44		)		313				(44		)
into cost of revenue (effective portion)
Gain (loss) recognized in income (ineffective portion and amount excluded		(10		)		43				(50		)		11
from effectiveness testing)
Derivatives Not Designated as Hedging Instruments
Gain (loss) recognized in exchange rate gain (loss), net		$	4,432			$	(996	)		$	3,490			$	4,880
Options and Warrants Related to Our Convertible Notes
In connection with our convertible debt offering in December 2012, we purchased call options on our common stock. The call options give us the right to purchase up to approximately 14.0 million shares of our common stock at $32.83 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the underlying debt. Additionally, we sold warrants, which give the purchasers of the warrants the right to purchase up to approximately 14.0 million shares of our common stock at $37.59 per share, subject to certain adjustments.
In connection with our convertible debt offering in September 2010 and subsequent partial repurchase in December 2012, we purchased call options on our common stock and sold warrants. The remaining call options give us the right to purchase up to approximately 850,000 shares of our common stock at $29.64 per share, subject to certain adjustments, and the remaining warrants give the counterparty the right to purchase up to approximately 850,000 shares of our common stock at $34.88 per share, subject to certain adjustments.
In accordance with the authoritative guidance, we concluded that these call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2017 and 2015 Notes occur.
Concentration of Credit Risk
Financial instruments which subject us to potential credit risk consist of our cash and cash equivalents, short-term and long-term available-for-sale investments, foreign currency derivative contracts, and trade accounts receivable.
We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and holding investments with maturities that maintain safety and liquidity. We place our cash and cash equivalents with high credit quality financial institutions. Deposits with these financial institutions may exceed the amount of insurance provided; however, these deposits typically are redeemable upon demand. Therefore we believe the financial risks associated with these financial instruments are minimal.
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms. We perform ongoing credit evaluations of our customers, and generally we do not require collateral on our accounts receivable. We estimate the need for allowances for potential credit losses based on historical collection activity and the facts and circumstances relevant to specific customers and we record a provision for uncollectible accounts when collection is uncertain. To date, we have not experienced significant credit related losses.
We are exposed to credit losses in the event of nonperformance by the banks with which we transact foreign currency contracts. We currently hold foreign exchange forward contracts with two counterparties. Our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We manage this credit risk by executing foreign currency contracts with major financial institutions with a Moody's and Standard & Poor's long-term debt rating of at least A/A2, and monitoring the credit ratings of our counterparties on a periodic basis.
In connection with the issuance of our 2015 Notes and our 2017 Notes, we purchased call options from counterparties. Non-performance by the counterparties under these call options would potentially expose us to dilution of our common stock to the extent our stock price exceeds the conversion price (in the case of the 2015 Notes and the 2017 Notes).
We purchase integrated circuits and other key components for use in our products. For certain components, which are currently single sourced, there are relatively few sources of supply. Although we believe that other suppliers could provide similar components on comparable terms, establishment of additional or replacement suppliers cannot be accomplished quickly. Any significant supply interruption could have a material adverse effect on our business, financial condition and results of operations. For further discussion, see “Risk Factors—Our manufacturing operations are dependent upon third party suppliers, some of which are sole-sourced, which makes us vulnerable to supply problems, price fluctuations and manufacturing delays.”
Fair Value Measurements
Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.
•	Level 1—Valuations based on quoted prices for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of money market funds and U.S. Treasury and agency debt securities.
•	Level 2—Valuations based on quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data, such as alternative pricing sources with reasonable levels of price transparency. Our Level 2 assets consist of corporate debt securities including commercial paper, corporate bonds, certificates of deposit and foreign currency forward contracts.
•	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Our Level 3 liability includes the contingent consideration related to the Crux and AtheroMed acquisitions and the other liability related to the Sync-Rx acquisition.
We utilize a third-party pricing service to assist us in obtaining fair value pricing for our investments. Pricing for certain securities is based on proprietary models. Inputs are documented in accordance with the fair value disclosure hierarchy. We also utilize third-party financial institutions to assist us in obtaining fair value pricing for our foreign currency forward contracts.
Contingent consideration arrangements obligate us to pay former shareholders of an acquired entity if specified future events occur or conditions are met such as the achievement of certain technological milestones or the achievement of targeted revenue milestones. We measure such liabilities using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. We used various key assumptions, such as the probability of achievement of the agreed milestones and the discount rate, in our determination of the fair value of contingent consideration. We monitor the fair value of the contingent consideration and the subsequent revisions are reflected in our unaudited consolidated statements of operations. For a further discussion on the key assumptions used in determining the fair value and the change in the estimated fair value of the contingent consideration during the three and nine months ended September 30, 2014, refer to Note 2, "Acquisitions and Acquisition-Related Items".
In connection with the Sync-Rx acquisition, we recorded a contingent liability related to a government grant received to develop underlying technologies. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technologies for which grant proceeds were received. We measure such liability using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. The grant was recorded as other liabilities at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. We monitor the fair value of the contingent liability and the subsequent revisions are reflected in our Statements of Operations. For a further discussion on the key assumptions used in determining the fair value, refer to Note 2, "Acquisitions and Acquisition-Related Items - Sync-Rx Acquisition".
During the three and nine months ended September 30, 2014 and 2013, no transfers were made into or out of the Level 1, 2, or 3 categories.
Financial assets and liabilities measured at fair value on a recurring basis are summarized below at September 30, 2014 and December 31, 2013 (in thousands):
		Fair Value Measurements at September 30, 2014
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	19,141			$	19,141			$	—			$	—
Money market funds		12,818				12,818				—				—
Corporate debt securities		140,894				—				140,894				—
Foreign currency forward contracts		7,718				—				7,718				—
Non-current:
Corporate debt securities		44,244				—				44,244				—
Foreign currency forward contracts		140				—				140				—
Total assets measured at fair value		$	224,955			$	31,959			$	192,996			$	—
Liabilities:
Current:
Foreign currency forward contracts		$	27			$	—			$	27			$	—
Other liabilities, current portion		95				—				$	—			95
Contingent consideration, current portion (1)		365				—				—				365
Non-current:
Other liabilities		1,036				—				—				1,036
Contingent consideration		53,379				—				—				53,379
Total liabilities measured at fair value		$	54,902			$	—			$	27			$	54,875
-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.3 million at September 30, 2014.
		Fair Value Measurements at December 31, 2013
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	98,436			$	98,436			$	—			$	—
Money market funds		8,723				8,723				—				—
Corporate debt securities		164,638				—				164,638				—
U.S. Treasury and agency debt securities		66,137				66,137				—				—
Foreign currency forward contracts		2,907				—				2,907				—
Non-current:
Corporate debt securities		11,727				—				11,727				—
U.S. Treasury and agency debt securities		23,023				23,023				—				—
Foreign currency forward contracts		81				—				81				—
Total assets measured at fair value		$	375,672			$	196,319			$	179,353			$	—
Liabilities:
Current:
Foreign currency forward contracts		$	1,415			$	—			$	1,415			$	—
Contingent consideration, current portion (1)		3,750				—				—				3,750
Non-current:
Other liabilities		1,249				—				—				1,249
Contingent consideration		29,888				—				—				29,888
Total liabilities measured at fair value		$	36,302			$	—			$	1,415			$	34,887
-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.
Inventories
Inventories consist of the following (in thousands):
		September 30, 2014				31-Dec-13
Finished goods (1)		$	37,325			$	27,237
Work-in-process		13,243				12,051
Raw materials		25,774				21,682
		$	76,342			$	60,970
-1	Finished goods inventory includes consigned inventory of $6.1 million and $5.6 million at September 30, 2014 and December 31, 2013, respectively.
Intangible Assets
Intangible assets consisted of the following (in thousands):
		30-Sep-14
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	121,807			$	22,337			$	99,470			12.3
Licenses		7,366				7,125				241				9
Customer relationships		4,213				4,066				147				6.2
Patents and trademarks		14,594				3,297				11,297				13.9
Covenant not to compete		600				208				392				3
		148,580				37,033				111,547				12.1
Intangible assets not yet subject to amortization
In-process research and development		13,260				—				13,260				n/a
		$	161,840			$	37,033			$	124,807
		December 31, 2013
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	57,507			$	16,393			$	41,114			8.6
Licenses		7,441				7,102				339				8.8
Customer relationships		4,441				4,312				129				6.1
Patents and trademarks		13,668				2,894				10,774				13.2
Covenant not to compete		300				108				192				3
		83,357				30,809				52,548				9.2
Intangible assets not yet subject to amortization
In-process research and development		5,560				—				5,560				n/a
		$	88,917			$	30,809			$	58,108
-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
At September 30, 2014, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
2014	2,917
2015	11,366
2016	11,141
2017	10,570
2018	10,514
Thereafter	65,039
	$	111,547
Restructuring Activity
Disposables Manufacturing Transition to Costa Rica Initiative
During the second quarter of 2013, our management approved plans to consolidate and transition our manufacturing resources related to the manufacturing of disposables to Costa Rica. Activities under this restructuring plan were initiated in the second quarter of 2013 and are expected to be substantially completed by mid-2015. We estimate that this restructuring plan will result in total pre-tax charges of approximately $2.8 million, all of which are one-time termination benefits, including severance payments and continuing medical benefits.
A summary of the activities related to this initiative is presented below (in thousands):
		Employee Termination Cost
Balance at 01/01/2013		$	—
Restructuring charges during 2013		333
Payments during 2013		(333		)
Balance at 12/31/2013		$	—
Restructuring charges during nine months ended 9/30/2014		251
Payments during nine months ended 09/30/2014		(251		)
Balance at 9/30/2014		$	—
Strategic Reorganization Initiative
During the third quarter of 2013, our management evaluated various development projects, product lines and functional areas in an effort to reprioritize and reallocate our resources within our distribution, research and development, and clinical programs to focus on development and commercial efforts that we believe better advance our key strategies. The key elements under this restructuring plan include the discontinuation of development programs for our forward-looking IVUS, or FL.IVUS, forward-looking intracardiac echocardiography, or FL.ICE, and optical computed tomography, or OCT, intravascular coronary imaging development programs, the termination of the commercial sale of the ReFLOW product line, and a modest reorganization of several functional areas and business units within the Company.
Activities under this restructuring plan were initiated in the third quarter of 2013 and were substantially completed during the second quarter of 2014. This restructuring resulted in total pre-tax charges of approximately $18.6 million, of which approximately $6.4 million resulted or will result in cash outlay. The following provides a summary of the total costs associated with the plan by major type of cost (in thousands):
Type of Cost		Total Estimated Amount
Employee termination benefits		$	2,659
Asset impairments		12,221
Other associated costs		3,713
Total		$	18,593
A summary of the restructuring charges related to this initiative is presented below (in thousands):
		Employee Termination Benefits				Asset Impairments				Other Associated Costs				Total
Balance at 01/01/2013		$	—			$	—			$	—			$	—
Restructuring charges during 2013		2,867				11,402				4,772				19,041
Payments/impairments during 2013		(797		)		(11,402		)		—				(12,199		)
Balance at 12/31/2013		$	2,070			$	—			$	4,772			$	6,842
Restructuring charges during 2014		$	(210	)		818				(1,056		)		(448		)
Payments/impairments during 2014		$	(1,337	)		(818		)		(3,716		)		(5,871		)
Balance at 09/30/2014		523				—				—				523
The employee termination benefits include severance payments and continuing medical and other benefits. The asset impairments are related to the discontinued programs and include impairment of property, plant and equipment assets, impairment of intangible assets and other tangible asset impairments. The other associated costs include the contract termination costs related to our purchase and lease commitments, and other costs directly related to the restructuring activities. The $1.1 million reduction in other associated costs during the nine months ended September 30, 2014 is primarily from negotiating a favorable settlement on a contract termination. Reductions in employee termination benefits are the result of final severance costs being less than previously estimated.
All charges were recorded in the restructuring charges line item within our unaudited condensed consolidated statement of operations.
Both restructuring initiatives are related to our medical segment.
Debt
In December 2012, we issued $460 million aggregate principal amount of 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on June 1 and December 1, commencing on June 1, 2013.
In September 2010, we issued $115 million aggregate principal amount of 2.875% Convertible Senior Notes due 2015, or the 2015 Notes, in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on March 1 and September 1, commencing on March 1, 2011. In December 2012, in connection with the issuance of the 2017 Notes, we repurchased $90 million of the $115 million in aggregate principal amount of the 2015 Notes.
The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes are reflected in our unaudited condensed consolidated balance sheets as follows (in thousands):
		September 30, 2014				December 31, 2013
Debt:
2.875% Convertible Senior Notes due 2015:
Principal amount		$	25,000			$	25,000
Unamortized discount of liability component		(1,006		)		(1,818		)
Unamortized debt issuance costs		(112		)		(204		)
Carrying value of liability component		23,882				22,978
1.75% Convertible Senior Notes due 2017:
Principal amount		460,000				460,000
Unamortized discount of liability component		(60,440		)		(72,902		)
Unamortized debt issuance costs		(7,515		)		(9,064		)
Carrying value of liability component		392,045				378,034
Equity—net carrying value
2.875% Convertible Senior Notes due 2015		$	452			$	452
1.75% Convertible Senior Notes due 2017		89,415				89,415
The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
	September 30, 2014				December 31, 2013
2.875% Convertible Senior Notes due 2015	$	24,885			$	25,950
1.75% Convertible Senior Notes due 2017	399,349				456,320
Total	$	424,234			$	482,270

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Loss Contingency [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	St. Jude Medical and LightLab Litigation Settlement
	On August 7, 2014, Volcano and its wholly-owned subsidiary, Axsun Technologies, Inc., or Axsun, and together with Volcano, the Volcano Parties, entered into a Settlement, Release, License Agreement, and Covenants Not To Sue, or the Agreement, with St. Jude Medical, Inc., or St. Jude, and its affiliates St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB, St. Jude Medical S.C., Inc., and LightLab Imaging, Inc., or LightLab, (collectively, the “St. Jude Parties”), to settle all currently ongoing litigation among the Volcano Parties and the St. Jude Parties. The settlement covers the following civil actions:
	•	LightLab Imaging, Inc. v. Axsun Technologies, Inc. and Volcano Corporation, in the Massachusetts Superior Court and the Massachusetts Supreme Judicial Court, or the Massachusetts Proceeding;
	•	Axsun Technologies, Inc. and Volcano Corporation v. LightLab Imaging, Inc., in the Delaware Chancery Court;
	•	LightLab Imaging, Inc. v. Axsun Technologies, Inc. and Volcano Corporation, in the Delaware Chancery Court;
	•	St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB, and St. Jude Medical S.C., Inc. v. Volcano Corporation, in the United States District Court for the District of Delaware;
	•	St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB, and St. Jude Medical S.C., Inc. v. Volcano Corporation, in the United States District Court for the District of Delaware;
	•	Volcano Corporation v. St. Jude Medical, Cardiovascular and Ablation Technologies Division, Inc.; St. Jude Medical, Cardiology Division, Inc.; St. Jude Medical, U.S. Division; St. Jude Medical S.C., Inc.; and St. Jude Medical Systems AB, in the United States District Court for the District of Delaware and the United States Court of Appeals for the Federal Circuit; and
	•	St. Jude Medical, Cardiology Division, Inc., v. Volcano Corporation, and Michelle K. Lee, Deputy Director, U.S. Patent and Trademark Office, in the United States Patent and Trademark Office and the United States Court of Appeals for the Federal Circuit.
	No payments are being made in connection with the Agreement.
	Pursuant to the Agreement, the parties agreed to cause each of the Litigations to be dismissed with prejudice and to not seek appellate review of a recent decision issued in the Massachusetts Proceeding.
	The Agreement contains mutual releases covering all claims that the Volcano Parties or the St. Jude Parties, or their respective affiliates, have or may have against the other in connection with the Litigations.
	The Agreement contains covenants not to sue by each party for (i) infringement of any of the patents that are the subject of any of the Litigations, (ii) infringement of any of the other party’s patents (subject to specified exceptions) by a party’s current products, products in the field of functional measurement for which regulatory approval is submitted before August 7, 2016, or features of those products, (iii) misappropriation of certain claimed trade secrets communicated each way between Axsun and LightLab and (iv) claims of any nature that relate to any of the Litigations. The covenants described in the preceding sentence do not extend to any: (a) patent infringement claims by St. Jude with respect to any (1) wireless communication of physiological pressure sensor data between a sensor and a receiver, or (2) products for intravascular optical coherence tomography (OCT); (b) patent infringement claims by Volcano with respect to any (1) iFR® patents or (2) products for intravascular ultrasound (i.e., IVUS products); or (c) products of an assignee existing prior to the assignment.
	The agreement contains licenses by each party to the other party of the patents that are the subject of the Litigations.
	Each party to the Agreement also agreed not to challenge the validity or enforceability of any of the patents that are the subject of any of the Litigations during the term of the Agreement, unless such party is accused of infringing the applicable patent. The Agreement terminates on August 7, 2036.
	Litigation-LightLab
	On January 7, 2009, LightLab Imaging, Inc., or LightLab, which was acquired by St. Jude Medical, Inc., or St. Jude, in 2010, filed a complaint against us and our wholly owned subsidiary, Axsun, in the Superior Court of Massachusetts, Suffolk County, seeking injunctive relief and unspecified damages, or the Massachusetts Action. The complaint included allegations that Volcano interfered with an agreement between Axsun and LightLab and with LightLab's advantageous business relationship with Axsun, breach of contract by Axsun, that Axsun and Volcano misappropriated LightLab's confidential information and trade secrets, and violated Chapter 93A, a Massachusetts statute that provides for recovery of up to three times damages plus attorney's fees (93A).
	On April 7, 2011, the court entered an Amended Final Judgment, in the Massachusetts Action: a) in favor of Volcano and Axsun on LightLab's claims for trade secret misappropriation on items 1-30 on LightLab's list of alleged trade secrets, b) ordered Volcano and Axsun to collectively pay $600,000 in damages and $4.5 million in attorneys' fees, c) in favor of LightLab on its claims against Axsun for breach of contract, breach of implied covenant of good faith and fair dealing, for violation of 93A, and misappropriation of trade secrets for disclosing three particular items to Volcano in December 2008 - the specifications for the two lasers provided by Axsun to LightLab and one Axsun laser prototype made in 2008, d) in favor of LightLab on its claims against Volcano for intentional interference with a contract and advantageous business relationship, unjust enrichment, violation of 93A, and misappropriation of trade secrets for the same three trade secrets described above. In addition, the Court denied a majority of LightLab's requested injunctions, and entered limited injunctive relief, none of which management believes have a material effect upon Volcano.
	LightLab appealed various decisions of the Court including, a) the Court's pre-trial rulings excluding certain lost profits damages evidence that LightLab sought to introduce at trial; b) the Court's decisions adverse to LightLab's claims for trade secret misappropriation in items 1-30 of LightLab's alleged list of trade secrets, including various rulings requiring evidence of use or intent to use as a prerequisite for injunctive relief; c) the Court's post-trial decisions denying permanent injunctive relief that LightLab requested as terms of the Final Judgment; and; d) the denial of LightLab's motion to alter or amend the Final Judgment, which motion sought to obtain additional declaratory relief barring Axsun from “supplying” tunable lasers to Volcano. Volcano and Axsun did not cross appeal the Amended Final Judgment in 2011, and Volcano and Axsun satisfied their payment obligations under the Amended Final Judgment by Volcano paying LightLab approximately $5.4 million. The Massachusetts Supreme Judicial Court issued a ruling in Volcano and Axsun's favor on July 28, 2014.
	In February 2010, Volcano and Axsun commenced an action in the Delaware Chancery Court, or the Chancery Court Action, against LightLab seeking a declaration of Volcano and Axsun's rights with respect to certain OCT technology, the High Definition Swept Source. LightLab then filed a counter-claim that included a claim against Axsun and Volcano for violations of 93A. This case has been stayed until such time as Volcano has achieved certain development and regulatory milestones.
	Additionally, on May 24, 2011, LightLab commenced a separate action in Delaware Chancery Court, or the Second Chancery Court Action, against Volcano and Axsun alleging that Axsun is inappropriately assisting Volcano in the development of a third-party laser. The complaint seeks injunctive relief and unspecified damages. After Volcano and Axsun moved to dismiss the Second Chancery Court Action, LightLab filed an amended complaint against Volcano and Axsun, adding additional allegations regarding misappropriation of trade secrets. This case has been stayed indefinitely.
	In January 2014, Volcano requested the Chancery Court dismiss the Chancery Court Actions. The Chancery Court has not ruled on this motion.
	As described above, these actions were settled on August 7, 2014.
	Litigation - St. Jude Medical
	On July 27, 2010, St. Jude Medical filed a lawsuit against Volcano in federal district court in Delaware (collectively, with the counterclaims described below, the Delaware Patent Action), alleging that our pressure guide wire products infringe five patents owned by St. Jude Medical. St. Jude Medical is seeking injunctive relief and monetary damages. This action does not involve OCT technology and is separate from the Massachusetts Action.
	On September 20, 2010, Volcano filed its response, in which we denied the allegations that our PrimeWire® products infringe any valid claim of St. Jude Medical's asserted patents. In addition, Volcano filed a counterclaim in which we alleged that St. Jude Medical's PressureWire® products and its RadiAnalyzer® Xpress product infringe three Volcano patents. In our counterclaim, Volcano sought injunctive relief and monetary damages. Trials on the St. Jude Medical patents and Volcano's patents were held in October 2012.
	On October 12, 2012, the court entered summary judgment for Volcano with respect to one of St. Jude Medical's asserted patents. On October 19, 2012, a jury found in favor of Volcano on the remaining four St. Jude Medical patents, finding that two of the patents were invalid and that Volcano did not infringe two of the patents. On October 22, 2012, Volcano voluntarily dismissed its claims against St. Jude Medical with respect to one of Volcano's patents. On October 25, 2012, a jury found in favor of St. Jude Medical with respect to Volcano's asserted patents. In conjunction with the trial, St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a pressure sensing guide wire patent). Post-trial motions are pending or remain available to the parties in the case. Volcano and St. Jude have stipulated to a confidential damages amount.
	On April 9, 2012, St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB and St. Jude Medical S.C. filed a sealed complaint in the United States District Court for the District of Delaware alleging that Volcano Corporation infringes United States Patent No. 6,565,514. Trial will be in December 2014 in this case.
	On April 16, 2013, Volcano filed suit in Federal District Court in Delaware against St. Jude Medical, Cardiovascular and Ablation Technologies Division, Inc., St. Jude Medical, Cardiology Division, Inc., St. Jude Medical, U.S. Division, St. Jude Medical S.C. Inc., and St. Jude Medical Systems AB, (collectively, “St. Jude”) for infringement of Volcano's recently issued United States Patent Nos. 8,419,647 and 8,419,648 both entitled “Ultra Miniature Pressure Sensor.” Volcano's complaint accuses St. Jude's PressureWire® Certus and PressureWire® Aeris cardiac pressure sensing guide wire products (the “Accused Guide Wires”) and St. Jude's RadiAnalyzer® Xpress Measurement System, Ilumien® PCI Optimization System and Quantien® Integrated FFR Platform, which are used with the Accused Guide Wires, of infringing the patented methods of United States Patent No. 8,419,647. Volcano's complaint also accuses the Accused Guide Wires of infringing the patented device claims of United States Patent No. 8,419,648. A claim construction hearing was held in November 2013, and a ruling adverse to Volcano was issued in January 2014. In February 2014, the parties submitted a joint stipulation to the Court agreeing that the Accused Guide Wires do not infringe Volcano’s patents under the Court’s claim construction ruling. The Court entered judgment in March 2014 and Volcano has appealed to the Federal Circuit Court of Appeals, which will likely hear the appeal prior to the end of 2014.
	As described above, these actions were settled on August 7, 2014.
	Litigation - CardioSpectra
	On March 27, 2012, Christopher E. Banas, et al., filed a lawsuit against Volcano in federal district court in the Northern District of California, alleging claims for breach of contract, breach of fiduciary duty, and breach of the implied covenant of good faith and fair dealing based on Volcano's acquisition of CardioSpectra in 2007. Specifically, plaintiffs assert that Volcano has failed to comply with the terms and the alleged implied obligations of the Merger Agreement relating to potential milestone payments. CardioSpectra was in the business of developing OCT technology; however, this litigation is separate from the Massachusetts Action.
	On May 14, 2012, Volcano moved to dismiss the complaint in its entirety. The motion sought to dismiss the breach of fiduciary duty and implied covenant claims without leave for amendment, and to dismiss the breach of contract claim with leave to amend. By order dated August 6, 2012, the Court granted Volcano's motion as to all issues with leave to amend. The plaintiffs filed a Second Amended Complaint on August 20, 2012, which included a single claim for breach of the Merger Agreement. In addition, the plaintiffs identified in the Second Amended Complaint are listed as Christopher E. Banas and Paul Castella in their respective capacities as Shareholder Representatives under the Merger Agreement. Volcano answered the Second Amended Complaint on September 4, 2012, and in the same document Volcano asserted several affirmative defenses. In March 2014, the Court granted Volcano's motion for summary judgment and entered judgment in favor of Volcano. The plaintiffs have filed a notice of appeal. Volcano filed a petition to recover its attorneys’ fees as the prevailing party pursuant to the Merger Agreement. Volcano is awaiting the Court’s order.
	Litigation - Other
	In November 2012, we became aware through newspaper reports in the Italian media that a former employee of ours was under criminal investigation for an alleged violation of Italian anti-bribery laws. We also learned that Volcano Europe B.V.B.A., our wholly-owned subsidiary, had temporarily been prohibited from establishing new contractual relationships with hospitals that are part of the Italian national health system. Following a court hearing, the temporary prohibition was lifted. The Italian public prosecutor's request that such prohibition be reinstituted was denied. The Italian public prosecutor is alleging that the approximately €5,000 that we paid to an Italian state-employed physician for conducting a training session was paid in an effort to influence the outcome of a clinical trial.
	The Company believes the lawsuits and other matter described above are without merit, and intends to vigorously defend against or prosecute, as applicable, the matters described above.
	We may also be a party to various other claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred and were not material in any period reported. Additionally, we assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Any provisions are reviewed at least quarterly and are adjusted to reflect the impact and status of settlements, rulings, advice of counsel and other information and events pertinent to a particular matter. Based on its experience, the Company also believes that the damage amounts claimed in the lawsuits disclosed above are not a meaningful indicator of the Company's potential liability. At this time, we are not able to predict or estimate the ultimate outcome or range of possible losses relating to the lawsuits, claims or counterclaims described above. However, we believe that the ultimate disposition of these matters, individually and in the aggregate, including the matters discussed above, will not have a material impact on our consolidated results of operations, financial position or cash flows. Our evaluation of the likely impact of these matters could change in the future, as litigation is inherently unpredictable, and unfavorable outcomes and/or defense costs, depending upon the amount and timing, could have a material adverse effect on our results of operations, financial position, or cash flows in future periods.
	Operating Leases
	Rent expense for our facilities leases is being recognized on a straight-line basis over the respective minimum lease terms.
	Commitments
	We have obligations under non-cancelable purchase commitments. The majority of these obligations related to inventory, primarily raw materials. At September 30, 2014, the future minimum payments under these non-cancelable purchase commitments totaled $80.3 million. Approximately $76.1 million of these commitments will require payment in 12 months, of which $75.8 million of these commitments will require payment prior to December 31, 2014. The remaining amount will require payments on various dates through 2016.
	We have commitments to provide funding for various clinical studies, for which we will be billed as services are performed under these agreements. At September 30, 2014, the remaining obligation under these agreements collectively is insignificant to our financial condition. In addition, we have entered into agreements with other third parties to sponsor clinical studies. Generally, we contract with one or more clinical research sites for a single study and no one agreement is material to our consolidated results of operations or financial condition. We are usually billed as services are performed based on enrollment and are required to make payments over periods ranging from less than one year up to five years. Our actual payments under these agreements will vary based on enrollment.
	At September 30, 2014, we have a commitment to purchase an additional $2.0 million of preferred shares in an existing cost-method investment in a private company. This commitment will expire in February 2015 if the option is not exercised by the private company.
	Indemnification
	Our supplier, distributor and collaboration agreements generally include certain provisions for indemnification against liabilities if our products are recalled, infringe a third party’s intellectual property rights or cause bodily injury due to alleged defects in our products. Many of our customer agreements also contain indemnification obligations in favor of our customers. In addition, we have agreements with our present and former directors and executive officers indemnifying them against liabilities arising from service in their respective capacities to Volcano. We maintain directors’ and officers’ insurance policies that may limit our exposure to such liabilities. To date, we have not incurred any material costs as a result of such indemnifications and have not accrued any liabilities related to such obligations in the accompanying unaudited condensed consolidated financial statements.
	Sole source suppliers
	We rely on a number of sole source suppliers to supply certain of our products, including our transducers and substrates used in our catheters. We do not carry significant inventory of transducers or substrates. If we had to change suppliers, we expect that it would take 6 to 24 months to identify appropriate suppliers, complete design work and undertake the necessary inspections and testing before the new transducers and substrates would be available. We are not parties to supply agreements with these suppliers but instead use purchase orders as needed.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Share Repurchase Program
	On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received a total of 4,705,683 shares of our common stock, of which 3,557,137 shares of our common stock were delivered in December 2013 and 1,148,546 shares of our common stock were delivered in March 2014.
	All of our repurchases were treated as effective retirements of the purchased shares and therefore reduced reported shares issued and outstanding by the number of shares repurchased. In addition, the Company recorded the excess of the purchase price over the par value of the common stock as a reduction to additional paid-in capital.
	Equity Compensation Plans
	Our Amended and Restated 2005 Equity Compensation Plan, or the 2005 Amended Plan, provides for an aggregate of 21,572,558 shares of our common stock that may be issued or transferred to our employees, non-employee directors and consultants.
	At September 30, 2014, we have granted stock options, time-vested restricted stock units, or RSUs, and performance-based RSUs, or PRSUs, under the 2005 Amended Plan. Stock options previously granted under the 2000 Long Term Incentive Plan that are canceled or expired will increase the shares available for grant under the 2005 Amended Plan. In addition, employees have purchased shares of the Company’s common stock under the 2007 Employee Stock Purchase Plan, or the Purchase Plan. According to the terms of the Purchase Plan, the number of shares of common stock available for issuance under the Purchase Plan was automatically increased by 600,000 shares on January 1, 2014. At September 30, 2014, 6,049,248 shares and 432,288 shares remained available to grant under the 2005 Amended Plan and the Purchase Plan, respectively.
	On February 12, 2014, our Compensation Committee adopted, under the terms of the 2005 Amended Plan, the 2014 Long Term Incentive Plan, or LTIP, and granted PRSUs under such LTIP. The PRSUs will vest contingent on the achievement of our revenue goal, our revenue growth and relative total shareholder return, which is measured against the performance of a defined peer group. Half of the PRSUs are earned based on the achievement of our revenue goal and revenue growth, or the performance condition, and the remaining half of the PRSUs are earned based on the achievement of the revenue goal and the relative total shareholder return, or the market condition.
	The measurement period for the PRSUs granted under the LTIP with the performance condition is our 2014 and 2015 fiscal years. The performance condition awards can range from 0% to 200% of the number of original shares granted. If the pre-determined performance goal is met, shares of stock subject to the PRSUs with the performance condition granted to the recipient will begin to vest, with two-thirds vesting on the date of certification of achievement of the pre-determined performance goal, and the remaining one third vesting on December 31, 2016, subject to continued service.
	The measurement period for the PRSUs granted under the LTIP with the market condition is our 2014 and 2015 fiscal years. The market condition awards can range from 0% to 200% of the number of original shares granted. If the pre-determined market goal is met, shares of stock subject to the PRSUs with the market condition granted to the recipient will begin to vest, with two-thirds vesting on the date of certification of achievement of the pre-determined market goal, and the remaining one third vesting on December 31, 2016, subject to continued service.
	Fair Value Assumptions
	PRSUs with Performance Condition and RSUs
	The fair value of the PRSUs with performance condition and the RSUs is estimated using the market price of our common stock on the grant date.
	PRSUs with Market Condition
	The fair value of the PRSUs that include a market condition is estimated using a Monte Carlo simulation model at the grant date. The Monte Carlo method is a statistical simulation technique used to provide the grant date fair value of an award. The assumptions used in the Monte Carlo simulation to value our PRSUs with market condition are presented below:
		Three and nine months ended
		30-Sep-14
	Risk-free interest rate	0.30%
	Expected life / remaining measurement period (years)	1.9
	Estimated volatility	30.90%
	Expected dividends	None
	Weighted-average grant date fair value	$24.90
	The risk-free interest rate is based on the implied yield available on U.S. Treasury constant maturity securities with the substantially equivalent period as the market condition measurement period remaining as of the grant date, which is 1.9 years. We utilize the volatility of our own common stock over the remaining measurement period in determining the grant date fair value. We use a zero value of the expected dividend value factor since we have not declared dividends in the past and we do not anticipate declaring dividends in the foreseeable future.
	Stock Options
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2014		2013	2014		2013
	Risk-free interest rate	1.60%		1.30%	1.60%		0.80%
	Expected life (years)	4.6		4.6	4.6		4.2
	Estimated volatility	34.80%		41.90%	35.70%		39.30%
	Expected dividends	None		None	None		None
	Weighted-average grant date fair value	$4.76		$7.34	$5.61		$7.44
	The risk-free interest rate for periods within the contractual life of the stock option is based on the implied yield available on U.S. Treasury constant maturity securities with substantially equivalent remaining terms at the time of grant. We use our historical stock option exercise experience to estimate the expected life of our stock options. We utilize the volatility of our own common stock over the expected life in determining the grant date fair value. We use a zero value for the expected dividend value factor since we have not declared dividends in the past and we do not anticipate declaring dividends in the foreseeable future.
	Employee Stock Purchase Plan
	The first offering period under the Purchase Plan commenced in September 2007. The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2014		2013	2014		2013
	Risk-free interest rate	0.10%		0.10%	0.10%		0.10%
	Expected life (years)	0.5		0.5	0.5		0.5
	Estimated volatility	38.70%		29.60%	35.40%		30.00%
	Expected dividends	None		None	None		None
	Fair value of purchase right	$4.67		$5.53	$5.03		$5.21
	The risk-free interest rate is based on the implied yield available on the U.S. Treasury constant maturity securities for the six-month term of each offering period in effect at the beginning of the offering period. We utilize the volatility of our own common stock over the offering period in determining the purchase rights fair value. We use a zero value for the expected dividend value factor since we have not declared dividends in the past and we do not anticipate declaring dividends in the foreseeable future.
	Stock-Based Compensation Expense
	With the exception of PRSUs with performance condition, stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the entire award, which is generally the vesting period, net of estimated forfeitures.
	We recognize the estimated compensation cost of PRSUs with performance condition on a straight-line basis over the requisite service period for each vesting tranche of the award, net of estimated forfeitures.
	The following table sets forth stock-based compensation expense included in our unaudited condensed consolidated statements of operations (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Cost of revenues	$	144		$	196		$	465	$	583
	Selling, general and administrative	2,641			3,592			9,053		10,152
	Research and development	420			462			1,203		1,363
		$	3,205		$	4,250		$	10,721	$	12,098

Segment_and_Geographic_Informa

Segment and Geographic Information	9 Months Ended
	Sep. 30, 2014
Segment And Geographic Information [Abstract]	'
Segment And Geographic Information	'
	Segment and Geographic Information
	Our chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information about segment revenues by product and geographic region for purposes of making operating decisions and assessing financial performance. We have two reporting segments, the first being the medical segment which includes the manufacture, sale, discovery, development and commercialization of products for the diagnosis of atherosclerosis in the coronary arteries and peripheral vascular system. In addition we have an industrial segment which includes the discovery, development, manufacture and sale of micro-optical spectrometers and optical channel monitors to telecommunications and other industrial companies.
	We do not assess the performance of our segments on other measures of income or expense, such as depreciation and amortization, operating income or net income. We do not produce reports for, or measure the performance of, our segments on any asset-based metrics. Therefore, segment information is presented only for revenues by product.
	The following table sets forth our revenues by segment and product (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Medical segment:
	Consoles	$	9,508	$	10,964	$	28,243	$	31,469
	Single-procedure disposables:
	IVUS	44,909		46,024		139,771		143,869
	FM	31,504		27,869		92,421		83,345
	Other	9,697		8,809		28,940		25,725
	Sub-total medical segment	95,618		93,666		289,375		284,408
	Industrial segment	1,839		2,143		5,215		5,976
		$	97,457	$	95,809	$	294,590	$	290,384
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues (1):
	United States	$	49,647	$	46,673	$	145,947	$	139,076
	Japan	21,678		26,368		68,964		82,292
	Europe, the Middle East and Africa	20,329		17,371		61,941		51,512
	Rest of world	5,803		5,397		17,738		17,504
		$	97,457	$	95,809	294,590		$	290,384
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.
	At September 30, 2014, approximately 49% of our long-lived assets, excluding financial assets, are located in the U.S., approximately 38% are located in Costa Rica, approximately 8% are located in Japan, and approximately 5% are located in our remaining geographies. At December 31, 2013, approximately 50% of our long-lived assets, excluding financial assets, were located in the U.S., approximately 38% were located in Costa Rica, approximately 8% were located in Japan, and approximately 4% were located in our remaining geographies.
	At September 30, 2014 and December 31, 2013, goodwill of $150.9 million and $55.1 million, respectively, has been allocated entirely to our medical segment.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Income taxes are determined using an estimated annual effective tax rate applied against income, and then adjusted for the tax impacts of certain discrete items. The Company recorded an income tax benefit of $8.3 million during the nine months ended September 30, 2014, resulting in an effective benefit rate of 30.7%. The effective tax rate differs from the Federal statutory rate of 35.0% primarily due to foreign income tax rate differentials and nondeductible expenses such as certain stock compensation and acquisition related items.
	We recorded an income tax benefit of $10.2 million during the nine months ended September 30, 2013, resulting in an income tax benefit rate of 42.0%. During the nine months ended September 30, 2013, federal legislation was enacted within the U.S. that retroactively allowed the research and development tax credit for all of 2012 and extended the credit through the twelve months ending December 31, 2013. Because this legislation was enacted in 2013, the full benefit of the credit related to 2012 activities was recognized during the nine months ended September 30, 2013. In the absence of the 2012 federal research and development tax credit, our effective benefit tax rate for the nine months ended September 30, 2013 would have been 38.0%.
	Our effective tax benefit rate decreased for the nine months ended September 30, 2014 as compared to the nine months ended September 30, 2013. The decrease was primarily due to the expiration of the federal research and development tax credit in December 2013 and nondeductible expenses related to stock compensation. In addition to the above noted items, the effective tax rate during the nine months ended September 30, 2013 included tax benefits related to the 2012 federal research and development tax credit’s retroactive reinstatement in January 2013.
	During the three months ended September 30, 2014, certain stock options were exercised and certain shares related to restricted stock awards vested at times when the Company’s stock price was substantially lower than the fair value of those shares at the time of grant. As a result, the income tax deduction related to such shares is less than the expense previously recognized for book purposes. Such shortfalls reduce additional paid-in capital to the extent windfall tax benefits have been previously recognized. During the three months ended September 30, 2014, no shortfalls reduced additional paid-in capital and $787,000 of the shortfall was included in income tax expense.
	The Company evaluates the realizability of the deferred tax assets on a jurisdictional basis at each reporting date. Accounting for income taxes guidance requires that a valuation allowance be established when it is more-likely-than-not that all or a portion of the deferred tax assets will not be realized. As part of the evaluation, the Company reviews both positive and negative evidence to determine if a valuation allowance is needed.
	In 2013, the Company incurred a net loss, and is not projecting a return to profitability in 2014. As of September 30, 2014, management has evaluated the recoverability of its Federal deferred tax assets, including factors such as a consideration of forecasted operating results, in-process changes in its manufacturing processes, potential tax planning strategies, as well as the period of time that will transpire before the underlying deferred tax assets will expire. Based on this evaluation, management has concluded that it is more likely than not that the underlying deferred tax assets will be utilized prior to their expiration, and therefore continues to believe that the Federal deferred tax assets will be recovered.
	Further, during the fourth quarter of 2013, we concluded that it was more likely than not that we would not be able to realize our U.S. state and select foreign deferred tax assets. The Company’s continues to maintain the recorded valuation allowance against our U.S. state and select foreign deferred tax assets as of September 30, 2014.
	We will continue to assess the need for a valuation allowance on deferred tax assets by evaluating both positive and negative evidence that may exist. To the extent we establish or change the valuation allowance in a period, the tax effect will generally flow through the statement of operations. In the case of an acquired or merged entity, we will record valuation allowance on a deferred tax asset through purchase accounting procedures as an adjustment to goodwill at the acquisition date, if it is more likely than not that all or a portion of the acquired deferred tax assets will not be realized in the future. Any subsequent change to a valuation allowance established during purchase accounting within the measurement period of the acquisition (not to exceed twelve months) will also be recorded as an adjustment to goodwill, provided that such change relates to new information about the facts and circumstances that existed on the acquisition date.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis Of Presentation And Principles Of Consolidation	'
	The unaudited condensed consolidated financial statements of Volcano Corporation (“we,” “us,” “our,” “Volcano” or the “Company”) contained in this quarterly report on Form 10-Q include our financial statements and the financial statements of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the U.S., or GAAP. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2013.
Our Company	'
	The results of operations for the nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Reclassification	'
	Reclassification
	Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current year presentation.
Net Income (Loss) Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing consolidated net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing consolidated net loss by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period. Our potentially dilutive shares include outstanding common stock options, unvested restricted stock units, including those with performance or market conditions, and incremental shares issuable upon the conversion of the Convertible Senior Notes or upon exercise of the warrants relating to the Convertible Senior Notes. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income per share as discussed in the following paragraph. For the three months ended September 30, 2014 and 2013, 176,000 and 730,000 in the money option and award shares were dilutive for the period and potentially dilutive shares totaling 49.0 million and 21.5 million have not been included in the computation of diluted net income per share, as the result would be anti-dilutive. For the nine months ended September 30, 2014 and 2013, 571,000 and 872,000 in the money option and award shares were dilutive for the period and potentially dilutive shares totaling 31.7 million and 20.8 million have not been included in the computation of diluted net loss per share, as the result would be anti-dilutive.
	Diluted net loss per common share does not include any incremental shares related to the Convertible Senior Notes for the three and nine months ended September 30, 2014 and 2013. Because the principal amount of the Convertible Senior Notes will be settled in cash upon conversion, only the conversion spread relating to the Convertible Senior Notes may be included in our calculation of diluted net loss per common share. As such, the Convertible Senior Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2.875% Convertible Senior Notes due 2015, or the 2015 Notes, and $32.83 for the 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, subject to adjustments) of the Notes. In addition, the diluted net loss per common share does not include any incremental shares related to the exercise of the warrants related to the Notes for the three and nine months ended September 30, 2014 and 2013. The warrants will not have an impact on diluted net income (loss) per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the warrants issued in connection with the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
	The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes, are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
	On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received a total of 4,705,683 shares of our common stock (see Note 5 "Stockholders' Equity"), of which 3,557,137 shares of our common stock were delivered in December 2013 and 1,148,546 shares of our common stock were delivered in March 2014. The weighted average number of the shares received was removed from the denominator of the basic and diluted net loss per share calculation at the share delivery date.
	The basic and diluted net loss per common share calculations for the three and nine months ended September 30, 2014 and 2013 are as follows (in thousands, except per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss	$	(8,000	)	$	(8,456	)	$	(18,622	)	$	(14,005	)
	Weighted average common shares outstanding for basic	51,529			54,652			51,596			54,466
	Weighted average common shares outstanding for diluted	51,529			54,652			51,596			54,466
	Net loss per share:
	Basic	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)
	Diluted	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update, or ASU, 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. The updated guidance is effective for us beginning in fiscal year 2015. The Company is currently evaluating the new standard to determine the effect, if any, on our consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a single comprehensive model for accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for us beginning in fiscal year 2017 and early application is not permitted. The Company is currently evaluating the new standard to determine the effect, if any, on our consolidated financial statements.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations	'
	The basic and diluted net loss per common share calculations for the three and nine months ended September 30, 2014 and 2013 are as follows (in thousands, except per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss	$	(8,000	)	$	(8,456	)	$	(18,622	)	$	(14,005	)
	Weighted average common shares outstanding for basic	51,529			54,652			51,596			54,466
	Weighted average common shares outstanding for diluted	51,529			54,652			51,596			54,466
	Net loss per share:
	Basic	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)
	Diluted	$	(0.16	)	$	(0.15	)	$	(0.36	)	$	(0.26	)

Acquisitions_and_AcquisitionRe1

Acquisitions and Acquisition-Related Items (Tables)	9 Months Ended
	Sep. 30, 2014
AtheroMed Inc. [Member]	'
Business Acquisition [Line Items]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	'
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		30-Sep-14
		Three months ended			Nine months ended
	Fair value measurement at beginning of period / acquisition	$	43,145		$	43,000
	Change in fair value measurement included in operating expenses	1,783			1,928
	Contingent consideration settled	(15,053		)	(15,053		)
	Fair value measurement at end of period	29,875			29,875
Crux Acquisition [Member]	'
Business Acquisition [Line Items]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	'
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net of working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Fair value measurement at beginning of period	$	24,290		$	31,687		$	33,638		$	30,231
	Change in fair value measurement included in operating expenses	(421		)	881			(6,769		)	2,337
	Contingent consideration settled	—			—			(3,000		)	—
	Fair value measurement at end of period	23,869			32,568			23,869			32,568

Financial_Statement_Details_Ta

Financial Statement Details (Tables)	9 Months Ended
	Sep. 30, 2014
Financial Statement Details [Abstract]	'
Available-For-Sale Investments	'
	At September 30, 2014 and December 31, 2013, available-for-sale investments are detailed as follows (in thousands):
	At September 30, 2014
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	140,927			$	29			$	62			$	140,894
	Short-term available-for-sale investments		$	140,927			$	29			$	62			$	140,894
	Long-term:
	Corporate debt securities		$	44,317			$	—			$	73			$	44,244
	Long-term available for sale investments		$	44,317			$	—			$	73			$	44,244
	At December 31, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	164,570			$	72			$	4			$	164,638
	U.S. Treasury and agency debt securities		66,153				2				18				66,137
	Short-term available-for-sale investments		$	230,723			$	74			$	22			$	230,775
	Long-term:
	Corporate debt securities		$	11,697			$	30			$	—			$	11,727
	U.S. Treasury and agency debt securities		23,008				15				—				23,023
	Long-term available for sale investments		$	34,705			$	45			$	—			$	34,750
Available-For-Sale Investments That Are In An Unrealized Loss Position	'
	Available-for-sale investments that are in an unrealized loss position at September 30, 2014 and December 31, 2013 are detailed as follows (in thousands):
			At September 30, 2014
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	106,244			$	135
			At December 31, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	21,226			$	4
	U.S. Treasury and agency debt securities		40,982				18
			$	62,208			$	22
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	'
	The following tables summarize the location and fair values of derivative instruments on our unaudited condensed consolidated balance sheets (in thousands) at September 30, 2014 and December 31, 2013. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		At September 30, 2014
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	3,685			Other current liabilities		$	1
	Foreign exchange forward contracts	Other long-term assets		140				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			3,825						1
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		4,033				Other current liabilities		26
	Total Derivatives Not Designated as Hedging Instruments			4,033						26
	Total Derivatives			$	7,858					$	27
		As of December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	954			Other current liabilities		$	251
	Foreign exchange forward contracts	Other long-term assets		81				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			1,035						251
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		1,953				Other current liabilities		1,164
	Total Derivatives Not Designated as Hedging Instruments			1,953						1,164
	Total Derivatives			$	2,988					$	1,415
Offsetting Assets and Liabilities	'
	The following table provides information (in thousands) as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.
		As of September 30, 2014
						Gross Amount Not Offset on the Balance Sheet
		Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
	Derivative Assets
	Foreign exchange forward contracts	$	7,858			$	(27	)		—			$	7,831
	Derivative Liabilities
	Foreign exchange forward contracts	(27		)		27				—			—
	Total	$	7,831			—				—			7,831
		As of December 31, 2013
						Gross Amount Not Offset on the Balance Sheet
		Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
	Derivative Assets
	Foreign exchange forward contracts	$	2,988			$	(1,415	)		—			$	1,573
	Derivative Liabilities
	Foreign exchange forward contracts	(1,415		)		1,415				—			—
	Total	$	1,573			—				—			1,573
Derivative Instruments, Gain (Loss)	'
	The following table summarizes the effect of our foreign exchange forward contracts on our unaudited Condensed Consolidated Statements of Operations (in thousands).
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014				2013
	Derivatives Designated as Hedging Instruments
	Gain (loss) recognized in other comprehensive income on foreign currency		$	4,243			$	(727	)		$	3,585			$	(719	)
	forward contracts (effective portion)
	Gain (loss) reclassified from accumulated other comprehensive income		16				(44		)		313				(44		)
	into cost of revenue (effective portion)
	Gain (loss) recognized in income (ineffective portion and amount excluded		(10		)		43				(50		)		11
	from effectiveness testing)
	Derivatives Not Designated as Hedging Instruments
	Gain (loss) recognized in exchange rate gain (loss), net		$	4,432			$	(996	)		$	3,490			$	4,880
Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis	'
	Financial assets and liabilities measured at fair value on a recurring basis are summarized below at September 30, 2014 and December 31, 2013 (in thousands):
			Fair Value Measurements at September 30, 2014
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	19,141			$	19,141			$	—			$	—
	Money market funds		12,818				12,818				—				—
	Corporate debt securities		140,894				—				140,894				—
	Foreign currency forward contracts		7,718				—				7,718				—
	Non-current:
	Corporate debt securities		44,244				—				44,244				—
	Foreign currency forward contracts		140				—				140				—
	Total assets measured at fair value		$	224,955			$	31,959			$	192,996			$	—
	Liabilities:
	Current:
	Foreign currency forward contracts		$	27			$	—			$	27			$	—
	Other liabilities, current portion		95				—				$	—			95
	Contingent consideration, current portion (1)		365				—				—				365
	Non-current:
	Other liabilities		1,036				—				—				1,036
	Contingent consideration		53,379				—				—				53,379
	Total liabilities measured at fair value		$	54,902			$	—			$	27			$	54,875
	-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.3 million at September 30, 2014.
			Fair Value Measurements at December 31, 2013
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	98,436			$	98,436			$	—			$	—
	Money market funds		8,723				8,723				—				—
	Corporate debt securities		164,638				—				164,638				—
	U.S. Treasury and agency debt securities		66,137				66,137				—				—
	Foreign currency forward contracts		2,907				—				2,907				—
	Non-current:
	Corporate debt securities		11,727				—				11,727				—
	U.S. Treasury and agency debt securities		23,023				23,023				—				—
	Foreign currency forward contracts		81				—				81				—
	Total assets measured at fair value		$	375,672			$	196,319			$	179,353			$	—
	Liabilities:
	Current:
	Foreign currency forward contracts		$	1,415			$	—			$	1,415			$	—
	Contingent consideration, current portion (1)		3,750				—				—				3,750
	Non-current:
	Other liabilities		1,249				—				—				1,249
	Contingent consideration		29,888				—				—				29,888
	Total liabilities measured at fair value		$	36,302			$	—			$	1,415			$	34,887
	-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.
Inventories	'
	Inventories consist of the following (in thousands):
			September 30, 2014				31-Dec-13
	Finished goods (1)		$	37,325			$	27,237
	Work-in-process		13,243				12,051
	Raw materials		25,774				21,682
			$	76,342			$	60,970
	-1	Finished goods inventory includes consigned inventory of $6.1 million and $5.6 million at September 30, 2014 and December 31, 2013, respectively.
Intangible Assets By Major Class	'
	Intangible assets consisted of the following (in thousands):
			30-Sep-14
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	121,807			$	22,337			$	99,470			12.3
	Licenses		7,366				7,125				241				9
	Customer relationships		4,213				4,066				147				6.2
	Patents and trademarks		14,594				3,297				11,297				13.9
	Covenant not to compete		600				208				392				3
			148,580				37,033				111,547				12.1
	Intangible assets not yet subject to amortization
	In-process research and development		13,260				—				13,260				n/a
			$	161,840			$	37,033			$	124,807
			December 31, 2013
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	57,507			$	16,393			$	41,114			8.6
	Licenses		7,441				7,102				339				8.8
	Customer relationships		4,441				4,312				129				6.1
	Patents and trademarks		13,668				2,894				10,774				13.2
	Covenant not to compete		300				108				192				3
			83,357				30,809				52,548				9.2
	Intangible assets not yet subject to amortization
	In-process research and development		5,560				—				5,560				n/a
			$	88,917			$	30,809			$	58,108
	-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
Future Amortization Expense Of Intangible Assets	'
	At September 30, 2014, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
	2014	2,917
	2015	11,366
	2016	11,141
	2017	10,570
	2018	10,514
	Thereafter	65,039
		$	111,547
Carrying Values Of The Liability And Equity Components Of The Notes	'
	The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes are reflected in our unaudited condensed consolidated balance sheets as follows (in thousands):
			September 30, 2014				December 31, 2013
	Debt:
	2.875% Convertible Senior Notes due 2015:
	Principal amount		$	25,000			$	25,000
	Unamortized discount of liability component		(1,006		)		(1,818		)
	Unamortized debt issuance costs		(112		)		(204		)
	Carrying value of liability component		23,882				22,978
	1.75% Convertible Senior Notes due 2017:
	Principal amount		460,000				460,000
	Unamortized discount of liability component		(60,440		)		(72,902		)
	Unamortized debt issuance costs		(7,515		)		(9,064		)
	Carrying value of liability component		392,045				378,034
	Equity—net carrying value
	2.875% Convertible Senior Notes due 2015		$	452			$	452
	1.75% Convertible Senior Notes due 2017		89,415				89,415
Schedule of Fair Value Of Notes	'
	The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
		September 30, 2014				December 31, 2013
	2.875% Convertible Senior Notes due 2015	$	24,885			$	25,950
	1.75% Convertible Senior Notes due 2017	399,349				456,320
	Total	$	424,234			$	482,270
Schedule of Restructuring Reserve by Type of Cost	'
	A summary of the activities related to this initiative is presented below (in thousands):
			Employee Termination Cost
	Balance at 01/01/2013		$	—
	Restructuring charges during 2013		333
	Payments during 2013		(333		)
	Balance at 12/31/2013		$	—
	Restructuring charges during nine months ended 9/30/2014		251
	Payments during nine months ended 09/30/2014		(251		)
	Balance at 9/30/2014		$	—
	A summary of the restructuring charges related to this initiative is presented below (in thousands):
			Employee Termination Benefits				Asset Impairments				Other Associated Costs				Total
	Balance at 01/01/2013		$	—			$	—			$	—			$	—
	Restructuring charges during 2013		2,867				11,402				4,772				19,041
	Payments/impairments during 2013		(797		)		(11,402		)		—				(12,199		)
	Balance at 12/31/2013		$	2,070			$	—			$	4,772			$	6,842
	Restructuring charges during 2014		$	(210	)		818				(1,056		)		(448		)
	Payments/impairments during 2014		$	(1,337	)		(818		)		(3,716		)		(5,871		)
	Balance at 09/30/2014		523				—				—				523
Restructuring and Related Costs	'
	The following provides a summary of the total costs associated with the plan by major type of cost (in thousands):
	Type of Cost		Total Estimated Amount
	Employee termination benefits		$	2,659
	Asset impairments		12,221
	Other associated costs		3,713
	Total		$	18,593

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Assumptions Used	'
	The assumptions used in the Monte Carlo simulation to value our PRSUs with market condition are presented below:
		Three and nine months ended
		30-Sep-14
	Risk-free interest rate	0.30%
	Expected life / remaining measurement period (years)	1.9
	Estimated volatility	30.90%
	Expected dividends	None
	Weighted-average grant date fair value	$24.90
Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions	'
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2014		2013	2014		2013
	Risk-free interest rate	1.60%		1.30%	1.60%		0.80%
	Expected life (years)	4.6		4.6	4.6		4.2
	Estimated volatility	34.80%		41.90%	35.70%		39.30%
	Expected dividends	None		None	None		None
	Weighted-average grant date fair value	$4.76		$7.34	$5.61		$7.44
Fair Value Of Stock Option Under The Purchase Plan, Weighted-Average Assumptions	'
	The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2014		2013	2014		2013
	Risk-free interest rate	0.10%		0.10%	0.10%		0.10%
	Expected life (years)	0.5		0.5	0.5		0.5
	Estimated volatility	38.70%		29.60%	35.40%		30.00%
	Expected dividends	None		None	None		None
	Fair value of purchase right	$4.67		$5.53	$5.03		$5.21
Table Of Stock-Based Compensation Expense	'
	The following table sets forth stock-based compensation expense included in our unaudited condensed consolidated statements of operations (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Cost of revenues	$	144		$	196		$	465	$	583
	Selling, general and administrative	2,641			3,592			9,053		10,152
	Research and development	420			462			1,203		1,363
		$	3,205		$	4,250		$	10,721	$	12,098

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment And Geographic Information [Abstract]	'
Schedule Of Revenues By Segment And Product	'
	The following table sets forth our revenues by segment and product (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Medical segment:
	Consoles	$	9,508	$	10,964	$	28,243	$	31,469
	Single-procedure disposables:
	IVUS	44,909		46,024		139,771		143,869
	FM	31,504		27,869		92,421		83,345
	Other	9,697		8,809		28,940		25,725
	Sub-total medical segment	95,618		93,666		289,375		284,408
	Industrial segment	1,839		2,143		5,215		5,976
		$	97,457	$	95,809	$	294,590	$	290,384
Schedule Of Revenues By Geography	'
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues (1):
	United States	$	49,647	$	46,673	$	145,947	$	139,076
	Japan	21,678		26,368		68,964		82,292
	Europe, the Middle East and Africa	20,329		17,371		61,941		51,512
	Rest of world	5,803		5,397		17,738		17,504
		$	97,457	$	95,809	294,590		$	290,384
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

4 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 02, 2013

Sep. 30, 2010

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Accelerated Share Repurchase Program [Member]

Accelerated Share Repurchase Program [Member]

Accelerated Share Repurchase Program [Member]

Accelerated Share Repurchase Program [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

Options Held [Member]

Options Held [Member]

Warrant [Member]

Warrant [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dilutive shares not included in the computation of diluted net income (loss) per share

176,000

730,000

571,000

872,000

'

'

'

'

'

'

'

'

'

'

Potentially dilutive shares not included in the computation of diluted net income (loss) per share

49,000,000

21,500,000

31,700,000

20,800,000

'

'

'

'

'

'

'

'

'

'

Initial effective conversion price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$29.64

$32.83

'

'

Convertible senior notes, interest rate

'

'

'

'

'

'

'

'

2.88%

1.75%

2.88%

1.75%

'

'

Investment warrants exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$34.88

$37.59

Stock repurchase program, authorized amount

'

'

'

'

'

'

'

$200,000,000

'

'

'

'

'

'

Accelerated share repurchases, settlement (payment) or receipt

'

'

'

'

'

'

'

$100,000,000

'

'

'

'

'

'

Common stock repurchase/retirement, shares

'

'

'

'

1,148,546

3,557,137

4,705,683

'

'

'

'

'

'

'

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]	'	'	'	'
Net loss	($8,000)	($8,456)	($18,622)	($14,005)
Weighted average common shares outstanding for basic	51,529	54,652	51,596	54,466
Weighted average common shares outstanding for diluted	51,529	54,652	51,596	54,466
Net loss per share:	'	'	'	'
Basic (in dollars per share)	($0.16)	($0.15)	($0.36)	($0.26)
Diluted (in dollars per share)	($0.16)	($0.15)	($0.36)	($0.26)

Acquisitions_and_AcquisitionRe2

Acquisitions and Acquisition-Related Items (AtheroMed Acquisition - Narrative) (Details) (USD $)

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Jun. 17, 2014

Sep. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Jun. 17, 2014

Dec. 31, 2013

Jun. 17, 2014

Jun. 17, 2014

Sep. 30, 2014

Jun. 17, 2014

Jun. 17, 2014

Sep. 30, 2014

Jun. 17, 2014

Sep. 30, 2014

Sep. 30, 2014

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

AtheroMed Inc. [Member]

Developed Technology Rights [Member]

In Process Research and Development [Member]

Appropriate and Timely Filing of 510(k) [Member]

Appropriate and Timely Filing of 510(k) [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Level 3 [Member]

Level 3 [Member]

Level 3 [Member]

Level 3 [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid related to acquisitions, net of cash acquired

$114,791,000

$15,000,000

'

$116,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash acquired from acquisition

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination, contingent consideration arrangements, amount of contingent consideration settled, liability

'

'

'

'

15,053,000

15,053,000

'

'

'

'

'

15,000,000

'

'

'

'

'

'

Contingent consideration, at fair value

'

'

'

'

29,875,000

29,875,000

43,145,000

'

43,000,000

'

'

'

14,000,000

'

'

29,000,000

'

'

Business combination, contingent consideration arrangements, range of outcomes, estimated amount

'

'

'

'

'

'

'

'

'

'

'

'

'

39,400,000

'

'

'

'

Fair value inputs, discount rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11.00%

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, low

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,800,000

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, high

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,200,000

'

'

'

Business combination, contingent consideration, fair value input, commercial sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59,900,000

89,900,000

Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles

'

'

'

'

'

'

'

'

'

61,900,000

9,000,000

'

'

'

'

'

'

'

Goodwill

$150,882,000

'

$55,087,000

'

'

'

'

$95,800,000

'

'

'

'

'

'

'

'

'

'

Acquisitions_and_AcquisitionRe3

Acquisitions and Acquisition-Related Items Acquisitions and Acquisition-Related Items (AtheroMed Acquisition - Contingent Consideration Rollforward) (Details) (USD $)	9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			AtheroMed Inc. [Member]	AtheroMed Inc. [Member]	AtheroMed Inc. [Member]	AtheroMed Inc. [Member]
					Operating Expense [Member]	Operating Expense [Member]
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'	'	'	'	'
Fair value measurement at beginning of period	'	'	$43,145	$43,000	'	'
Change in fair value measurement included in operating expenses	-16,900	0	'	'	1,783	1,928
Contingent consideration settled	'	'	-15,053	-15,053	'	'
Fair value measurement at end of period	'	'	$29,875	$29,875	'	'

Acquisitions_and_AcquisitionRe4

Acquisitions and Acquisition-Related Items Acquisitions and Acquisition-Related Items (Pioneer Acquisition - Narrative) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Aug. 30, 2013
			Pioneer Plus Re-entry Catheter [Member]
Business Acquisition [Line Items]	'	'	'
Total purchase price	'	'	$15,000,000
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill	'	'	12,700,000
Goodwill	$150,882,000	$55,087,000	$1,500,000

Acquisitions_and_AcquisitionRe5

Acquisitions and Acquisition-Related Items (Crux Acquisition - Narrative) (Details) (Crux Acquisition [Member], USD $)	3 Months Ended		9 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					Appropriate and Timely Filing of 510(k) [Member]	Various Sales Milestones [Member]	Various Sales Milestones [Member]	Various Sales Milestones [Member]	Various Sales Milestones [Member]
								Minimum [Member]	Maximum [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business combination, contingent consideration arrangements, amount of contingent consideration settled, liability	$0	$0	$3,000,000	$0	$3,000,000	'	'	'	'
Fair value inputs, discount rate	'	'	'	'	'	14.00%	10.00%	'	'
Business combination, contingent consideration arrangements, range of outcomes, value, low	'	'	'	'	'	'	23,400,000	'	'
Business combination, contingent consideration arrangements, range of outcomes, value, high	'	'	'	'	'	'	64,300,000	'	'
Business combination, contingent consideration, fair value input, commercial sales	'	'	'	'	'	'	'	$94,400,000	$204,900,000

Acquisitions_and_AcquisitionRe6

Acquisitions and Acquisition-Related Items Acquisitions and Acquisition-Related Items (Crux Acquisition - Contingent Consideration Rollforward) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'	'	'
Change in fair value measurement included in operating expenses	'	'	($16,900)	$0
Crux Acquisition [Member]	'	'	'	'
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'	'	'
Fair value measurement at beginning of period	24,290	31,687	33,638	30,231
Change in fair value measurement included in operating expenses	'	881	'	2,500
Contingent consideration settled	0	0	-3,000	0
Fair value measurement at end of period	23,869	32,568	23,869	32,568
Crux Acquisition [Member] | Operating Expense [Member]	'	'	'	'
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'	'	'
Change in fair value measurement included in operating expenses	($421)	$881	($6,769)	$2,337

Acquisitions_and_AcquisitionRe7

Acquisitions and Acquisition-Related Items (Sync-Rx Acquisition and Acquisition Related Items - Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Nov. 26, 2012

Nov. 26, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

AtherMed, Inc. and Sync-Rx Ltd. [Member]

AtherMed, Inc. and Sync-Rx Ltd. [Member]

AtheroMed, Inc. and Crux Biomedical, Inc. [Member]

AtheroMed, Inc. and Crux Biomedical, Inc. [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux and Sync-Rx Acquisition [Member]

Crux and Sync-Rx Acquisition [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Government Grant to Develop Underlying Technology [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Government Grant to Develop Underlying Technology [Member]

Government Grant to Develop Underlying Technology [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other long-term debt

'

'

'

'

'

$1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value inputs, discount rate

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination, estimated commercial sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

256,100,000

'

298,300,000

'

Business acqusition, development grant, liability, repayment period (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'16 years

Contingent consideration, at fair value

'

'

'

'

'

1,900,000

'

'

'

'

32,568,000

32,568,000

23,869,000

24,290,000

33,638,000

31,687,000

30,231,000

'

'

'

'

'

'

Business combination, pro forma information, earnings or (loss) of acquiree since acquisition date, actual

-1,600,000

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related items

1,596,000

1,253,000

-3,809,000

3,742,000

'

'

244,000

1,000,000

'

'

'

'

'

'

'

'

'

358,000

810,000

'

'

'

'

Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability

'

'

($16,900,000)

$0

'

'

'

'

$1,400,000

($4,800,000)

$881,000

$2,500,000

'

'

'

'

'

'

'

'

'

'

'

Financial_Statement_Details_Na

Financial Statement Details (Narrative) (Details) (USD $)

9 Months Ended

15 Months Ended

1 Months Ended

9 Months Ended

Share data in Thousands, except Per Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2010

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]

Employee Severance [Member]

Employee Severance [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Warrant [Member]

Warrant [Member]

Call Options [Member]

Call Options [Member]

Restructuring Plan, 2013, Disposables Manufacturing Transition to Costa Rica Initiative [Member]

Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

1.75% Convertible Senior Notes Due 2017 [Member]

2.875% Convertible Senior Notes Due 2015 [Member]

Derivatives, Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period for investments, months

'22 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of foreign currency forward contracts

'

'

'

'

'

'

'

$120,400,000

$97,300,000

$56,400,000

$40,300,000

'

'

'

'

Accumulated other comprehensive income (loss), cumulative changes in net gain (loss) from cash flow hedges, effect net of tax

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to purchase common stock, number of shares

'

'

'

'

'

'

'

'

'

'

'

14,000

850

14,000

850

Purchase price of common stock (in dollars per derivative)

'

'

'

'

'

'

'

'

'

'

'

'

'

32.8286

29.64

Investment warrants exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$37.59

$34.88

'

'

Expected restructuring costs

'

18,593,000

2,800,000

2,659,000

'

'

'

'

'

'

'

'

'

'

'

Restructuring and related cost, expected cost, cash outlay

'

6,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

460,000,000

115,000,000

115,000,000

'

'

'

'

'

'

'

'

Convertible senior notes, interest rate

'

'

'

'

1.75%

'

2.88%

'

'

'

'

'

'

'

'

Repayments of long-term debt

'

'

'

'

'

$90,000,000

'

'

'

'

'

'

'

'

'

Financial_Statement_Details_Av

Financial Statement Details (Available-For-Sale Investments) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	'	$22
Available-for-sale Securities, Fair Value Disclosure	'	62,208
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	135	4
Available-for-sale Securities, Fair Value Disclosure	106,244	21,226
U.S. Treasury and Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	'	18
Available-for-sale Securities, Fair Value Disclosure	'	40,982
Short-term [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	140,927	230,723
Available-for-sale securities, Gross Unrealized Gains	29	74
Available-for-sale securities, Gross Unrealized Losses	62	22
Available-for-sale Securities, Fair Value Disclosure	140,894	230,775
Short-term [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	140,927	164,570
Available-for-sale securities, Gross Unrealized Gains	29	72
Available-for-sale securities, Gross Unrealized Losses	62	4
Available-for-sale Securities, Fair Value Disclosure	140,894	164,638
Short-term [Member] | U.S. Treasury and Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	'	66,153
Available-for-sale securities, Gross Unrealized Gains	'	2
Available-for-sale securities, Gross Unrealized Losses	'	18
Available-for-sale Securities, Fair Value Disclosure	'	66,137
Long-term [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	44,317	34,705
Available-for-sale securities, Gross Unrealized Gains	0	45
Available-for-sale securities, Gross Unrealized Losses	73	0
Available-for-sale Securities, Fair Value Disclosure	44,244	34,750
Long-term [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	44,317	11,697
Available-for-sale securities, Gross Unrealized Gains	0	30
Available-for-sale securities, Gross Unrealized Losses	73	0
Available-for-sale Securities, Fair Value Disclosure	44,244	11,727
Long-term [Member] | U.S. Treasury and Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	'	23,008
Available-for-sale securities, Gross Unrealized Gains	'	15
Available-for-sale securities, Gross Unrealized Losses	'	0
Available-for-sale Securities, Fair Value Disclosure	'	$23,023

Financial_Statement_Details_Av1

Financial Statement Details (Available-For-Sale Investments That Are In An Unrealized Loss Position) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	'	$62,208
Available-for-sale Securities, Gross Unrealized Losses	'	22
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	106,244	21,226
Available-for-sale Securities, Gross Unrealized Losses	135	4
U.S. Treasury and Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	'	40,982
Available-for-sale Securities, Gross Unrealized Losses	'	$18

Financial_Statement_Details_Fo

Financial Statement Details (Foreign Currency Forward Contract) (Details) (Foreign Exchange Forward [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	$7,858	$2,988
Derivative liability, fair value, gross liability	27	1,415
Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	3,825	1,035
Derivative liability, fair value, gross liability	1	251
Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	4,033	1,953
Derivative liability, fair value, gross liability	26	1,164
Other Current Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	3,685	954
Other Current Assets [Member] | Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	4,033	1,953
Other Current Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value, gross liability	1	251
Other Current Liabilities [Member] | Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value, gross liability	26	1,164
Other Noncurrent Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value, gross asset	140	81
Other Noncurrent Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value, gross liability	$0	$0

Financial_Statement_Details_Of

Financial Statement Details (Offsetting Assets and Liabilities) (Details) (Foreign Exchange Forward [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Foreign Exchange Forward [Member]	'	'
Offsetting Liabilities [Line Items]	'	'
Gross Amount of Recognized Assets (Liabilities)	($27)	($1,415)
Financial Instruments	27	1,415
Cash Collateral (Received) or Pledged	0	0
Net Amount	0	0
Offsetting Assets [Line Items]	'	'
Gross Amount of Recognized Assets (Liabilities)	7,858	2,988
Financial Instruments	-27	-1,415
Cash Collateral (Received) or Pledged	0	0
Net Amount	7,831	1,573
Gross Amount of Recognized Assets (Liabilities)	7,831	1,573
Financial Instruments	0	0
Cash Collateral (Received) or Pledged	0	0
Net Amount	$7,831	$1,573

Financial_Statement_Details_Ef

Financial Statement Details (Effect Of Foreign Exchange Forward Contracts On Consolidated Statements Of Income) (Details) (Foreign Exchange Forward [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Designated as Hedging Instrument [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)	$4,243	($727)	$3,585	($719)
Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)	16	-44	313	-44
Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)	-10	43	-50	11
Not Designated as Hedging Instrument [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in exchange rate gain (loss), net	$4,432	($996)	$3,490	$4,880

Financial_Statement_Details_Fi

Financial Statement Details (Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	$140,894,000		$230,775,000
Available-for-sale Securities, Noncurrent	44,244,000		34,750,000
Total assets measured at fair value	224,955,000		375,672,000
Total liabilities measured at fair value	54,902,000		36,302,000
Fair value of working capital receivable	1,300,000		1,200,000
Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Total assets measured at fair value	31,959,000		196,319,000
Total liabilities measured at fair value	0		0
Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Total assets measured at fair value	192,996,000		179,353,000
Total liabilities measured at fair value	27,000		1,415,000
Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Total assets measured at fair value	0		0
Total liabilities measured at fair value	54,875,000		34,887,000
Cash [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	19,141,000		98,436,000
Cash [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	19,141,000		98,436,000
Cash [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	0		0
Cash [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	0		0
Money Market Funds [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	12,818,000		8,723,000
Money Market Funds [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	12,818,000		8,723,000
Money Market Funds [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	0		0
Money Market Funds [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents, Current	0		0
Corporate Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	140,894,000		164,638,000
Available-for-sale Securities, Noncurrent	44,244,000		11,727,000
Corporate Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
Corporate Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	140,894,000		164,638,000
Available-for-sale Securities, Noncurrent	44,244,000		11,727,000
Corporate Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
U.S. Treasury and Agency Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	'		66,137,000
Available-for-sale Securities, Noncurrent	'		23,023,000
U.S. Treasury and Agency Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	'		66,137,000
Available-for-sale Securities, Noncurrent	'		23,023,000
U.S. Treasury and Agency Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	'		0
Available-for-sale Securities, Noncurrent	'		0
U.S. Treasury and Agency Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	'		0
Available-for-sale Securities, Noncurrent	'		0
Foreign Currency Forward Contracts [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts, current asset	7,718,000		2,907,000
Foreign currency forward contracts, non-current asset	140,000		81,000
Foreign currency forward contracts, current liability	27,000		1,415,000
Foreign Currency Forward Contracts [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts, current asset	0		0
Foreign currency forward contracts, non-current asset	0		0
Foreign currency forward contracts, current liability	0		0
Foreign Currency Forward Contracts [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts, current asset	7,718,000		2,907,000
Foreign currency forward contracts, non-current asset	140,000		81,000
Foreign currency forward contracts, current liability	27,000		1,415,000
Foreign Currency Forward Contracts [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts, current asset	0		0
Foreign currency forward contracts, non-current asset	0		0
Foreign currency forward contracts, current liability	0		0
Other Current Liabilities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	95,000		'
Other Current Liabilities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	0		'
Other Current Liabilities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	0		'
Other Current Liabilities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	95,000		'
Commitments [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration, current portion	365,000	[1]	3,750,000	[2]
Contingent consideration, non-current portion	53,379,000		29,888,000
Commitments [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration, current portion	0	[1]	0	[2]
Contingent consideration, non-current portion	0		0
Commitments [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration, current portion	0	[1]	0	[2]
Contingent consideration, non-current portion	0		0
Commitments [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Contingent consideration, current portion	365,000	[1]	3,750,000	[2]
Contingent consideration, non-current portion	53,379,000		29,888,000
Other Noncurrent Liabilities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	1,036,000		1,249,000
Other Noncurrent Liabilities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	0		0
Other Noncurrent Liabilities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	0		0
Other Noncurrent Liabilities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Other liabilities	$1,036,000		$1,249,000
[1]	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.3 million at September 30, 2014.
[2]	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.

Financial_Statement_Details_In

Financial Statement Details (Inventories) (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
Financial Statement Details [Abstract]	'		'
Finished goods	$37,325,000	[1]	$27,237,000	[1]
Work-in-process	13,243,000		12,051,000
Raw materials	25,774,000		21,682,000
Inventories	76,342,000		60,970,000
Consigned inventory	$6,100,000		$5,600,000
[1]	Finished goods inventory includes consigned inventory of $6.1 million and $5.6 million at September 30, 2014 and December 31, 2013, respectively.

Financial_Statement_Details_In1

Financial Statement Details (Intangible Assets By Major Class) (Details) (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	$161,840		$88,917
Accumulated Amortization	37,033		30,809
Net	124,807		58,108
Developed Technology [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	121,807		57,507
Accumulated Amortization	22,337		16,393
Net	99,470		41,114
Weighted average useful lives of intangible assets (in years)	'12 years 3 months 18 days	[1]	'8 years 7 months 6 days	[1]
Licenses [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	7,366		7,441
Accumulated Amortization	7,125		7,102
Net	241		339
Weighted average useful lives of intangible assets (in years)	'9 years	[1]	'8 years 9 months 18 days	[1]
Customer Relationships [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	4,213		4,441
Accumulated Amortization	4,066		4,312
Net	147		129
Weighted average useful lives of intangible assets (in years)	'6 years 2 months 12 days	[1]	'6 years 1 month 6 days	[1]
Patents and Trademarks [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	14,594		13,668
Accumulated Amortization	3,297		2,894
Net	11,297		10,774
Weighted average useful lives of intangible assets (in years)	'13 years 10 months 24 days	[1]	'13 years 2 months 12 days	[1]
Covenant Not to Compete [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	600		300
Accumulated Amortization	208		108
Net	392		192
Weighted average useful lives of intangible assets (in years)	'3 years	[1]	'3 years	[1]
Intangible Assets Subject to Amortization [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	148,580		83,357
Accumulated Amortization	37,033		30,809
Net	111,547		52,548
Weighted average useful lives of intangible assets (in years)	'12 years 1 month 6 days	[1]	'9 years 2 months 12 days	[1]
In Process Research and Development [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	13,260		5,560
Accumulated Amortization	0		0
Net	$13,260		$5,560
[1]	Weighted average life of intangible assets is presented excluding fully amortized assets.

Financial_Statement_Details_Fu

Financial Statement Details (Future Amortization Expense Of Intangible Assets) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Net	$124,807	$58,108
Intangible Assets Subject to Amortization [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
2014	2,917	'
2015	11,366	'
2016	11,141	'
2017	10,570	'
2018	10,514	'
Thereafter	65,039	'
Net	$111,547	$52,548

Financial_Statement_Details_Re

Financial Statement Details (Restructuring Rollforward) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring reserve, beginning balance	$6,842	$0
Restructuring charges	-448	19,041
Payments/impairments for restructuring	-5,871	-12,199
Restructuring reserve, ending balance	523	6,842
Employee Termination Benefits [Member] | Restructuring Plan, 2013, Disposables Manufacturing Transition to Costa Rica Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring reserve, beginning balance	0	0
Restructuring charges	251	333
Payments/impairments for restructuring	-251	-333
Restructuring reserve, ending balance	0	0
Employee Termination Benefits [Member] | Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring reserve, beginning balance	2,070	0
Restructuring charges	-210	2,867
Payments/impairments for restructuring	-1,337	-797
Restructuring reserve, ending balance	523	2,070
Asset Impairments [Member] | Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring reserve, beginning balance	0	0
Restructuring charges	818	11,402
Payments/impairments for restructuring	-818	-11,402
Restructuring reserve, ending balance	0	0
Other Associated Costs [Member] | Restructuring Plan, 2013, Strategic Reorganization Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring reserve, beginning balance	4,772	0
Restructuring charges	-1,056	4,772
Payments/impairments for restructuring	-3,716	0
Restructuring reserve, ending balance	$0	$4,772

Financial_Statement_Details_To

Financial Statement Details (Total Estimated Restructuring) (Details) (Restructuring Plan, 2013, Strategic Reorganization Initiative [Member], USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	$18,593
Employee Severance [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	2,659
Asset Impairments [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	12,221
Other Associated Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	$3,713

Financial_Statement_Details_Ca

Financial Statement Details (Carrying Values Of The Liability And Equity Components Of The Notes) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
2.875% Convertible Senior Notes Due 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount	$25,000	$25,000
Unamortized discount of liability component	-1,006	-1,818
Unamortized debt issuance costs	-112	-204
Carrying value of liability component	23,882	22,978
Equity - net carrying value	452	452
1.75% Convertible Senior Notes Due 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount	460,000	460,000
Unamortized discount of liability component	-60,440	-72,902
Unamortized debt issuance costs	-7,515	-9,064
Carrying value of liability component	392,045	378,034
Equity - net carrying value	$89,415	$89,415

Financial_Statement_Details_Li

Financial Statement Details (Liability and Equity Component Of Notes Measured At Fair Value) (Details) (Level 2 [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible senior notes	$424,234	$482,270
2.875% Convertible Senior Notes Due 2015 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible senior notes	24,885	25,950
1.75% Convertible Senior Notes Due 2017 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible senior notes	$399,349	$456,320

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details)	0 Months Ended	1 Months Ended	9 Months Ended		9 Months Ended
	Apr. 07, 2011	Nov. 30, 2012	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	USD ($)	EUR (€)	USD ($)	Cost Method Investment, Preferred Shares [Member]	Minimum [Member]	Maximum [Member]
				USD ($)
Loss Contingencies [Line Items]	'	'	'	'	'	'
Loss contingency, damages awarded, value	$600,000	'	'	'	'	'
Attorney's fees	4,500,000	'	'	'	'	'
Settlement payment obligation to third party	'	'	5,400,000	'	'	'
Alleged payment to influence outcome of clinical trial (in Euros)	'	5,000	'	'	'	'
Purchase commitments	'	'	80,300,000	'	'	'
Purchase commitments that require payments in 12 months	'	'	76,100,000	'	'	'
Commitments will require payments (in months)	'	'	'12 months	'	'	'
Purchase commitments that require payments in 3 months	'	'	75,800,000	'	'	'
Unrecorded unconditional purchase obligation	'	'	'	$2,000,000	'	'
Contractual payments due (in years)	'	'	'	'	'1 year	'5 years
Number of months needed replace sole source suppliers	'	'	'	'	'6 months	'24 months

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	0 Months Ended			9 Months Ended				1 Months Ended		4 Months Ended
	Jan. 02, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 02, 2013
	Amended Plan [Member]	Amended Plan [Member]	Purchase Plan [Member]	Performance Restricted Stock Units [Member]	Performance Restricted Stock Units [Member]	Performance Restricted Stock Units [Member]	Performance Restricted Stock Units [Member]	Accelerated Share Repurchase Program [Member]	Accelerated Share Repurchase Program [Member]	Accelerated Share Repurchase Program [Member]	Accelerated Share Repurchase Program [Member]
				Certification of Achievement of Pre-determined Market Goal [Member]	December 31, 2016, Subject to Continued Service [Member]	Minimum [Member]	Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Stock repurchase program, authorized amount	'	'	'	'	'	'	'	'	'	'	$200,000,000
Accelerated share repurchases, settlement (payment) or receipt	'	'	'	'	'	'	'	'	'	'	$100,000,000
Common stock repurchase/retirement, shares	'	'	'	'	'	'	'	1,148,546	3,557,137	4,705,683	'
Common stock, shares authorized	'	21,572,558	'	'	'	'	'	'	'	'	'
Share-based compensation arrangement by share-based payment award, number of additional shares authorized	600,000	'	'	'	'	'	'	'	'	'	'
Common stock issued in equity compensation plan	'	6,049,248	432,288	'	'	'	'	'	'	'	'
Share-based compensation arrangement by share-based payment award, equity instruments other than options, performance condition percentage of original shares granted	'	'	'	'	'	0.00%	200.00%	'	'	'	'
Share-based compensation arrangement by share-based payment award, equity instruments other than options, market condition percentage of original shares grantedShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Market Condition Percentage of Original Shares Granted	'	'	'	'	'	0.00%	200.00%	'	'	'	'
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage	'	'	'	66.67%	33.33%	'	'	'	'	'	'

Stockholders_Equity_Assumption

Stockholders' Equity (Assumptions Used to Value the Performance Restricted Stock Units with a Market Condition) (Details) (Performance Restricted Stock Units [Member], USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Performance Restricted Stock Units [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	0.30%	0.30%
Expected life (years)	'1 year 10 months 24 days	'1 year 10 months 24 days
Estimated volatility	30.90%	30.90%
Weighted-average grant date fair value (in dollars per share)	$24.90	$24.90

Stockholders_Equity_Fair_Value

Stockholders' Equity (Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions) (Details) (Stock Option [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock Option [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	1.60%	1.30%	1.60%	0.80%
Expected life (years)	'4 years 7 months 6 days	'4 years 7 months 6 days	'4 years 7 months 6 days	'4 years 2 months 12 days
Estimated volatility	34.80%	41.90%	35.70%	39.30%
Weighted-average grant date fair value (in dollars per share)	$4.76	$7.34	$5.61	$7.44

Stockholders_Equity_Fair_Value1

Stockholders' Equity (Fair Value Of Stock Option Under The Purchase Plan Weighted-Average Assumptions) (Details) (Purchase Option Under Purchase Plan [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Purchase Option Under Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	0.10%	0.10%	0.10%	0.10%
Expected life (years)	'6 months	'6 months	'6 months	'6 months
Estimated volatility	38.70%	29.60%	35.40%	30.00%
Fair value of purchase right (in dollars per share)	$4.67	$5.53	$5.03	$5.21

Stockholders_Equity_Table_Of_S

Stockholders' Equity (Table Of Stock-Based Compensation Expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	$3,205	$4,250	$10,721	$12,098
Cost of revenues	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	144	196	465	583
Selling, general and administrative	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	2,641	3,592	9,053	10,152
Research and development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	$420	$462	$1,203	$1,363

Segment_and_Geographic_Informa2

Segment and Geographic Information (Narrative) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
	segment
Segment Reporting Information [Line Items]	'	'
Number of reportable segments	2	'
Goodwill	$150,882	$55,087
United States [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	49.00%	50.00%
Costa Rica [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	38.00%	38.00%
Japan [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	8.00%	8.00%
Rest Of World [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	5.00%	4.00%

Segment_and_Geographic_Informa3

Segment and Geographic Information (Schedule Of Revenues By Segment And Product) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	$97,457	$95,809	$294,590	$290,384
Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	95,618	93,666	289,375	284,408
Industrial segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	1,839	2,143	5,215	5,976
Consoles [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	9,508	10,964	28,243	31,469
IVUS [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	44,909	46,024	139,771	143,869
FM [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	31,504	27,869	92,421	83,345
Other [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	$9,697	$8,809	$28,940	$25,725

Segment_and_Geographic_Informa4

Segment and Geographic Information (Schedule Of Revenues By Geography) (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	$97,457		$95,809		$294,590	$290,384
United States [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	49,647	[1]	46,673	[1]	145,947	139,076
Japan [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	21,678	[1]	26,368	[1]	68,964	82,292
Europe, The Middle East And Africa [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	20,329	[1]	17,371	[1]	61,941	51,512
Rest Of World [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	$5,803	[1]	$5,397	[1]	$17,738	$17,504
[1]	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income tax benefit	($3,971)	($4,392)	($8,266)	($10,156)
Effective income tax rate	'	'	30.70%	42.00%
U.S. federal statutory income tax rate	'	'	35.00%	'
Effective income tax rate, continuing operations excluding research and development tax credit	'	'	'	38.00%
Employee service share-based compensation, tax expense from compensation benefit	$787	'	'	'